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c-Abl is a non-receptor tyrosine kinase involved in various cell processes ranging 
from cell growth to cellular stress response. Mice carrying the null allele for c-Abl 
exhibit developmental abnormalities and complex phenotypes. My project attempts to 
address how c-Abl deficiency leads to the osteoporotic phenotype observed in mutant 
mice. 
 
c-Abl-/- osteoblasts show a reduction in proliferation potential and undergo premature 
senescence due to up-regulation of p16INK4a, a biomarker of senescence. The 
p16INK4a–mediated osteoblast senescence can be regulated by BMPs, which are major 
regulators of bone remodeling, through ERK1/2 and Id1 in an opposing fashion. 
Elevated p16INK4a levels were secondary to the down-regulation of Id1 and enhanced 
activation of ERKs, both known regulators of p16INK4a expression.  
 
Id1, a known target gene of the BMP pathway, was repressed in c-Abl-/- osteoblasts. 
Further investigation showed that c-Abl could regulate Id1 expression and was 
required for maximal Id1 induction by BMP2. This premature senescence could be 
rescued by c-Abl reconstitution or ectopic expression of Id1. c-Abl augments Id1 
expression by modulating the activation of Smads1/5/8, direct effectors of the BMP 
pathway. In addition, the expression of several other BMP target genes was found to 
be compromised by c-Abl deficiency. Hence, c-Abl played a positive role in BMP 
signaling and I found the link for c-Abl involvement via the regulation of BMP type I 
receptors (BMPR IA/IB), upstream activators of Smads. c-Abl was found to 
phosphorylate BMPR1A, on tyrosine residues Y453/457/458/467 found at the 
carboxy-terminus of BMPR1A. More importantly, co-immunoprecipitation studies 
 xviii
revealed that receptor complex formation between BMPR1 and BMPRII was 
compromised without the intact tyrosine residues on BMPR1A, validating the 
significance of c-Abl action on the BMP pathway. 
 
On the other hand, ERKs are positive regulators of p16INK4a and can be activated by 
BMPs via the TAB1-TAK1 complex. c-Abl repressed BMP-induced ERK activation 
over long periods of time by affecting the interaction of TAB1 with BMPR1A, 
forming the basis behind enhanced MAPK-ERK1/2 activation observed in c-Abl-/- 
osteoblasts. Moreover BMPs, secreted by osteoblasts, not only mediate osteoblast 
differentiation but also promote osteoprogenitor expansion via sustained Id1 
expression, by keeping p16INK4a expression repressed. Thus, through the actions of c-
Abl on BMPR1A, c-Abl deficiency shifts BMP signal transduction from Smad1/5/8 to 
favor MAPK-ERK1/2 activation, resulting in up-regulation of p16INK4a. For that 
reason, c-Abl fine-tuning of p16INK4a expression, in part by BMP signaling, is 
important for promoting osteoprogenitor cell expansion.  
 
These findings place c-Abl in BMP-mediated signaling pathways and establish its 
importance in osteoprogenitor expansion, linking osteoprogenitor senescence to senile 



















The following literature review provides background information for the results 
section (Chapter 3 to 8). It begins with an overview of c-Abl, a tyrosine kinase central 
to this research project. The themes of aging is explored at both the organism and 
cellular level, as well as in bone homeostasis whereby diseases such as osteoporosis 
arise from abnormal aging of the bones. Lastly, the BMP pathway, vital to these 
processes is reviewed in greater detail.  
 
 
1.1 The c-Abl tyrosine kinase 
 
 
Tyrosine kinases (TKs) are enzymes that catalyze the transfer of phosphate from ATP 
to tyrosine residues in polypeptides, and there are 90 TKs and 43 TK-like genes, 
comprising close to one-fifth of total protein kinases identified in the human genome 
(Krause and Van Etten, 2005). TKs can be broadly grouped into either receptor TKs 
or non-receptor TKs (NRTK). c-Abl (cellular-Abelson) is a NRTK, and is closely 
related to the c-Src and Src family of NRTKs as they share a homologous N-terminal 
portion. ARG (Abl-related gene, or ABL2) is the only known paralogue of c-Abl 
(Kruh et al., 1990).  
 
c-abl, a proto oncogene; came into discovery only after the isolation of A-MuLV 
(Abelson murine Leukemia Virus), which induced development of lymphosarcoma in 
mice (Abelson and Rabstein, 1970). c-Abl was found to be the host protein with 
kinase activity, while fusions with other viral component such as Gag-Abl (v-Abl) 
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render its transforming capability. The following subsections will briefly collate 
structural and functional studies done on c-Abl, and also its involvement in 
pathophysiology of CML. 
 
 
1.1.1 The c-Abl gene, isoforms and structure  
 
c-Abl is a 150 kDa protein that is highly conserved and expressed ubiquitously. It is 
present in most cellular compartments, including the nucleus. In humans, the c-Abl 
gene gives rise to two forms of mRNA products that are 5- and 6.5- kb in length, 
denoted type Ia and Ib as a result of alternative splicing from separate promoters 
found on the Abl gene. The murine versions of c-Abl are denoted as type I and IV, 
equivalents of human type Ia and Ib respectively. Similarly, two isoforms of ARG; A 
and B exists (Li, 2006). 
 
Figure 1.1A illustrates the structural domains of the c-Abl Ib protein. The proximal 
N-terminus at the cap region is important for lipid modification of c-Abl as it contains 
the consensus sequence for myristoylation, which is not present in type Ia (or I for 
murine) (Fig. 1.1B). The C14 myristoyl fatty acid at the amino terminus is essential for 
regulating c-Abl activation and is the main difference between the gene variants.  
Following the cap domain are the SH3 (Src-homology 3), SH2, and kinase domain 
(PTK), which are common to the Src family kinases. In contrast the large, C-terminal 
region spanning ~90 kDa is unique to c-Abl. The main sections found here are: a large 
DNA binding domain, an actin binding domain, three nuclear localization signals 
(NLS), one single nuclear export signal (NES) (Wen et al., 1996, Taagepera et al., 
1998). The features of the latter two domains confer the special ability of c-Abl to 
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shuttle between the cytoplasm and nucleus (Van Etten, 1999). Hence, the specific 
roles of c-Abl can be pre-determined by its localization.  
 
The ability of c-Abl to form fusion proteins with other genes gives rise to isoforms 
such as v-Abl (viral-Abl), BCR-ABL (Breakpoint cluster-ABL), and Tel-Abl. These 
gene fusions create oncogenes, as all three possess transformation ability, unlike 
tightly regulated c-Abl, which cannot transform cells even when overexpressed (Van 
Etten et al., 1989). v-Abl is a result of fusion between Gag viral protein (M-MulV) to 
the SH2 domain of c-Abl, and can be myristoylated, hence its exclusive localization 
in the cytoplasm. It possesses potent tyrosine kinase activity that is required for 
cellular transformation of cells such as myeloid cells and fibroblasts, and can induce 
pre-B cell leukemia in mice.  
 
BCR-ABL, on the other hand, is a fusion protein between the N-terminal sequences of 
BCR and almost full-length c-Abl. This fusion makes BCR-Abl constitutively active, 
unlike c-Abl that is normally held in an inactive form in the absence of stimulation. 
BCR-Abl is localized in the cytoplasm, with the exception of ectoposide-induced 
DNA damage that triggers its nuclear translocation (Dierov et al., 2004). The various 
fusions at different points of BCR exons create at least three isoforms that differ in 
their size: p185, p210, and p230. Differences in BCR-ABL isoforms and the cell it 
targets is likely to contribute to the type of leukemia formed. In the etiology of 
specific leukemias, expression of p210BCR-ABL was correlated with Chronic 
Myelogenous Leukemia (CML) in over 90% of cases, and estimated 33% of adult 
acute lymphoblastic leukemia (B-ALL) cases with Ph chromosome. p185BCR-ABL was 
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associated with the remaining adult Acute Myelogenous Leukemia cases unrelated 
with Ph chromosome, AML and lymphoma (Melo, 1996, Deininger et al., 2000). 
 
 
1.1.2 Abl biology using forward/reverse genetics 
 
c-Abl is expressed ubiquitously throughout mouse embryonic development, with 
higher expression in the thymus (Muller et al., 1982, Renshaw et al., 1988). In 
humans, high expression of c-Abl was found in hyaline cartilages, adipocytes and 
ciliated epithelium of adults, while in fetuses the heaviest expression was observed at 
the sites of endochondral ossification (O'Neill et al., 1997). The physiological 
functions of c-Abl have been studied mainly with the c-Abl knockout mice. Genetic 
studies of c-Abl-/- mice demonstrated its essential role in development. Mice carrying 
the null allele for c-Abl are mostly perinatal lethal. And those that survive the first 3 
days (<50%) exhibit several developmental abnormalities coupled with complex 
phenotypes such as shortened-lifespan, infertility, runtedness, thymus and spleen 
atrophies and osteoporosis (Schwartzberg et al., 1991, Tybulewicz et al., 1991). Some 
surviving homozygous mutants will develop megaesophagus and anal prolapse from 
the third month (Li et al., 2000). Through the generation of other c-Abl knockout 
lines bearing c-Abl deletion or truncation it was found that the carboxy-terminal 
region was critical for c-Abl function in vivo (Li et al., 2000). 
 
Mice deficient for c-Abl paralogue Arg are normal. However, mice deficient for both 
c-Abl and Arg are embryonic lethal at 11 dpc., with defects in neural tube closure and 
massive apoptosis and hemorrhage in the brains (Koleske et al. 1998). This suggests a 
role for c-Abl and Arg in early embryonic development,  with   Arg   sharing  some  


























Figure 1.1 The structural domains of c-Abl. (A) Illustration of the domain 
structures in mammalian c-Abl protein (Abl Ib) and below (B) the aligned cap 
sequences of human Abl Ia, Ib, ARG-A, ARG-B, and mouse c-Abl I and IV. 
Myristoylation sites are shaded in yellow and the conserved sequences of cap regions 





















Apart from genetic studies, c-Abl function was extensively studied from the cell 
biology perspective. Biochemical studies indicate that c-Abl can be activated by 
various growth factors such as transforming growth factor- (TGF) (Wilkes and 
Leof, 2006), epidermal growth factor (EGF) (Plattner et al, 1999), PDGF through 
phospholipase C-1 (PLC-1) (Plattner et al., 2003), mainly to promote cell 
proliferation. It also plays an important role cellular stress response as in the case of 
promoting apoptosis under DNA damage stress response by activating ATM-p53-p73 
pathway (Yuan et al., 1999), and in oxidative stress response via protein kinase C 
(PKC) (Li et al., 2004). Due to the presence of a huge actin binding domain, c-Abl 




1.1.3 Abl in transformation and therapeutics: BCR-ABL and STI571 
 
 
Chronic Myelogenous Leukemia (CML) is a clonal myeloproliferative disorder 
originating from the pluripotential stem cells of the bone marrow. This disease 
progresses in three stages, starting from the chronic phase, and followed the 
accelerated phase and lastly, the blast crisis phase. The transition to final two phases 
often display more aggressive and pleiotropic phenotypes, with a displacement of 
mature cells by immature blasts (Wong and Witte, 2004). Therefore, treatment of 
CML in the early stage holds better prognosis, and chances of remission. 
 
The majority of CML patients have the Philadelphia chromosome (Ph+), an abnormal 
reciprocal translocation between chromosomes 9 (containing c-Abl gene) and 22 
(BCR-break point gene) creating partner proteins (Rowley, 1973, Groffen et al., 1984, 
and Heisterkamp et al., 1985). This fusion holds a coiled-coil (CC) domain in the 
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BCR region that mediates oligomerization, which is crucial for its constitutively 
active kinase activity and remains a target region for therapeutic intervention 
(reviewed in Krause and Van Etten, 2005).  
 
Imatinib mesylate (Gleevec) was the first and most successful small molecular TK 
inhibitor tested on CML. It is a 2-phenylaminopyrimidine compound that can 
specifically inhibit four TKs: Abl, Arg, c-Kit and PDGF receptor (PDGFR) (Druker et 
al., 1996, Okuda et al., 2001) and induces complete hematologic and cytogenetic 
remissions in most chronic phase CML patients (O’Brien et al., 2003), with the 
overall survival rate of 90.8% (Cohen et al., 2005). 
 
The elucidation of intramolecular interaction between c-Abl kinase complexed with 
imatinib using crystallography led to the advanced understanding of the mechanism 
behind imatinib action (Nagar et al., 2003). The latch-clamp model of Abl 
autoinhibition reveals the conformational changes for c-Abl activation requires 
removal of myristoyl group, displacement of SH3 domain, along with activation of 
phosphor-tyrosine sites Y412 and/or Y245. Therefore, how BCR-ABL can maintain 
constant kinase activation stems from the loss of Cap domain which weakens the 
inhibitory effect of SH3-SH2 domains and more importantly the oligomerization 
ability of BCR-CC domain that can facilitate phosphorylation of Y412 (Harrison, 
2003, Hantschel and Superti-Furga, 2004). 
 
However, newer approaches to CML therapy is needed as a small percentage of 
chronic phase patients remain non-responsive to imatinib, and it does not work as well 
in accelerated and blast stages, with higher incidence of drug resistance in blast crisis 
patients that received treatment. Moreover, long-term treatment is mandatory as 
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imatinib acts to repress, but not remove BCR transcripts since it enforces Abl to adopt 
an inactive confirmation by binding to the conserved ATP-binding region. Long-term 
toxicity of imatinib is implicated as it can also repress c-Abl functions. Other 
pharmacological options to improve treatment involve the use of combination therapy 
(e.g. imatinib with interferon-α or farnesyl transferase inhibitors), small molecule 
inhibitor nutlin-1 to boost p53 levels. Also, newer designed inhibitors have been 
tested that are improved versions of imatinib, such as PD173955, AMN107 that 
inhibits only BCR-ABL, and dual inhibitors of Abl and Src such as AP23464. Other 
drugs created can also target imatinib-resistant BCR-ABL mutants (reviewed in Li, 
2006). The current known pathways that are involved in BCR-ABL pathogenesis will 






























1.2 Aging and senescence   
 
 
Aging is a universal, physiological process that marks the finite life-span of a multi-
cellular organism, which eventually leads to death. In aging, survival is challenged by 
deleterious changes that compromise the body’s capacity to function efficiently. The 
history and current understanding of factors involved in the biology of aging are 
described here, at both the organism and cellular level. 
  
 
1.2.1 Organismal aging 
 
 
The typical signs of aging in mice are phenotypes such as reduced life-span, 
osteopenia, graying hair, reduced weight, skin ulcerations and alopecia (Hasty et al., 
2003). In humans, these signs are also prevalent, along with neuronal, retinal 
degeneration and the increased risk of late-life cancers. Despite the physical 
similarities, the etiology of aging remains complex, as significant variations in aging 
phenotypes and individual lifespan have been reported across all species.  
 
Genetics was believed to be the basis for aging. There exist unique sets of pleiotropic 
genes that function to be beneficial during early life and turn harmful later in age, as 
natural selection becomes weak, labeled the “antagonistic pleiotropic theory” 
(Williams, 1957). Less well-received was the theory that aging was programmed, and 
the accumulation of mutations in genes that confer longevity causes aging. Yet, both 
theories have not been validated successfully since pleiotropic genes have not been 
singled out (Partridge and Gems, 2002), and no combination of mutations were found 
to abolish aging altogether, as seen with genetic manipulations on longevity model, 
the nematode C. elegans (Shaw et al., 1999).  
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Nevertheless, the “disposable soma theory” could account for the variations observed 
with aging. The act of natural selection was believed to conserve body’s resources to 
maintain processes such as growth, repair and reproduction. Aging begins when the 
body’s resources are stretched beyond their allocated limit to cater to additional 
functions such as injury or adaptation to weather. Thus, the exhaustion of resources to 
maintain optimum body functions is believed to disrupt the maximum lifespan 
potential of an organism (Kirkwood, 1977 and 2005, Kirkwood and Austad, 2000). 
Therefore, due to the lack of mechanistic conservation in aging, it remains 
complicated in understanding the reasons behind aging.  
  
 
1.2.2 Cellular senescence  
 
 
Cellular or replicative senescence is an in vitro phenomenon that occurs to cells in 
culture. Unlike tumor cells that can proliferate indefinitely, normal cultured cells were 
observed to possess a finite lifespan, or doubling time (Hayflick and Moorhead, 
1961).  The process of replicative senescence is a fundamental feature of somatic 
cells, and is characterized by cells undergoing permanent growth arrest at G1 phase 
(Campisi, 1997). Senescent cells adopt a typical physical appearance of a large, 
flattened morphology. More striking are the biochemical changes that distinguish a 
senescent cell from a pre-senescent cell. Senescent cells cease to divide but remain 
metabolically active. Apart from the irreversible block to cell proliferation, changes to 
expression of different sets of transcription factors, the increased resistance to 
apoptosis (Wang, 1995) and the secretion of various cytokines and matrix proteins 
makes a senescent cell alter its normal differentiated functions (Shelton et al., 1999, 
Itahana et al., 2004). With the knowledge obtained on senescence mostly from cell 
culture studies, an important caveat to be questioned is whether senescence takes 
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place in vivo. Campisi addressed this issue and strongly suggested that cells do 
undergo replicative senescence in vivo to contribute to aging, via several lines of 
evidence that included studies of cells passaged in intact animals (reviewed in 
Campisi, 1996 and 2001). 
 
The outcome of senescence can be a two-edged sword. Senescence remains an 
effective barrier against neoplastic transformation, linking cancer and aging as a 
tumor suppressive mechanism. Yet in contradiction, the presence of senescent cells 
can accumulate in aged tissues and disrupt tissue integrity and normal function 
through their altered actions such as the secretion of degradatory matrix proteins 
(Dimri et al., 1995, Millis et al., 1992). This in turn may promote cancer progression 
(Campisi, 2005).  
 
1.2.2.1 Replicative senescence versus premature senescence 
 
 
Senescence can be categorized into two types, replicative senescence which is 
attributed by telomerase (hence intrinsic), and non-replicative/premature senescence 
which occurs by telomere-independent mechanisms (extrinsic). This classification is 
important in distinguishing the different mechanisms of senescence that occurs 
between humans and mice. 
 
Intrinsic senescence relies on the expression of telomerase. The telomerase enzyme 
synthesizes telomeres, which function as a “cap” to keep chromosome length 
constant. To protect cells against genomic instability and cancer, it is believed 
senescence is triggered when cells acquire very short telomeres (Kim et al., 2002). 
However, only human germ cells and certain stem cells express telomerase, therefore 
most human somatic cells suffer from telomere attrition after each round of DNA 
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replication and become vulnerable to senescence. This cell-counting mechanism 
employed by human cells does not exist in mice as laboratory mice have been shown 
to possess extremely long telomeres (40-60 kb, in contrast with 5-15 kb in humans) 
(reviewed in Itahana et al., 2004). Hence, the senescence of murine cells is most 
likely to be induced by extrinsic or environmental factors. Figure 1.2 summarizes the 
two classes of senescence and the causative agents involved.  
 
 
1.2.3 The molecular basis of senescence 
 
 
Many intrinsic and extrinsic factors have been implicated to trigger senescence and 
different hypotheses were proposed along these lines. However, little is done to unify 
these theories as they remain rather unconnected, while it is generally believed that 
each of these causes work in combination to contribute to aging as a whole. 
 
One key intrinsic factor that affects the rate of aging is progressive telomere attrition 
that acts as a system to ‘count’ cell divisions and a potential tumor-protection 
mechanism (Wright and Shay, 2001). Yet, the differences in mouse and human 
telomere lengths demonstrate the species-specific disparity in regulating senescence.  
The increased levels of oxidative stress was found to be able to accelerate telomere 
loss (von Zglinicki, 2002), indicating innate and extrinsic factors may share 
similarities in signaling mechanisms. 
 
Genome maintenance is another important factor. Damage to DNA triggers sensors of 
DNA double strand breaks and leads to the recruitment of DNA repair foci to the site 
of damage. Defects in DNA repair systems increase the risk of somatic cell mutations, 















Figure 1.2. The two forms of senescence in mammalian cells. Extrinsic senescence 
(telomere independent) covers cell culture conditions, DNA damage by radiation or 
chemicals, oncogenic or mitogenic stimuli and exogenously overexpressed tumor 
suppressors such as p16INK4a. Intrinsic senescence occurs within the cell nucleus, a 
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important determinant in the rate of aging (Kirkwood, 2005), and human models for 
this form of aging are discussed in section 1.2.4. 
 
A major extrinsic factor for inducing senescence is the exposure of cells to cellular 
stresses. STASIS (stress or aberrant signaling-induced senescence) forms the basis of 
the numerous acute and chronic stress signals that confronts a pre-senescent cell 
(Shay and Roninson, 2004). Oxidative stress, in particular is common in cell culture 
conditions where higher physiological concentrations of O2 and the production of free 
radicals ROS (reactive oxygen species) can significantly accelerate senescence 
(Lundberg et al., 2000). For example, mild hyperoxia culture conditions could shorten 
a cell’s replicative lifespan and induce accelerated telomere shortening (von Zglinicki 
et al, 1995), while short term serum starvation in cells induced quiescence, and long 
term serum deprivation triggered senescence. The free radical theory of senescence 
may be valid in organismal aging as well, since p66SHC-/- mice were less sensitive to 
the toxic effects of ROS, and lived 30% longer than its wild type counterparts 
(Migliaccio et al., 1999). 
 
The relationship shared by oncogenes and senescence has been well established. 
Oncogene-induced senescence (OIS) describes the ability of oncogenes such as Myc, 
E1A or Ras to activate genes (p16INK4a and p19ARF) required for cell cycle arrest and 
induce senescence, when ectopically expressed (Serrano et al., 1997, Palmero et al., 
1998). OIS operate as a bona fide barrier to tumorigenesis in vivo (reviewed in Narita 
and Lowe, 2005), as the escape from senescence or immortality is important for 
malignant transformation to occur. In this case, senescence can be bypassed by 
introducing viral oncogenes (e.g. HPV-E6), that targets tumor suppressors p53 and 
 15
Rb, both of which must be functionally inactivated in order for human cells to 
circumvent senescence (Shay et al., 1991). Nevertheless, the mechanism of telomere 
shortening (replicative senescence) appears to be dispensible for ras-induced 
senescence, since prior ectopic expression of hTERT allowed fibroblasts to escape 
from replicative, but not ras-induced senescence (Wei and Sedivy, 1999). 
Furthermore, the immortalization of epithelial cells required additional mechanisms 
such as epigenetic modifications (p16INK4a methylation) as the expression of 
telomerase per se is insufficient to bypass senescence (Wright and Shay, 2001). 
Hence, it appears different senescence mechanisms are employed by cells and this 
may vary among species, cell type, or in different cell context. 
 
 1.2.3.1 Signaling pathways of senescence 
 
 
Despite the diverse stimuli in inducing a senescent state, only two signaling pathways 
have been shown to be responsible. Crucial to these pathways are the activation of 
two key tumor suppressor genes p53 and pRb (retinoblastoma) and their effectors 
cyclin-dependent kinase inhibitors (CDKIs) p19ARF and p16INK4a respectively, as 
illustrated in Figure 1.3. 
 
In the p53 pathway, p19ARF stabilizes p53 by interfering with its negative regulator 
MDM2. In turn, p21CIP1 gets induced by p53, to promote cell cycle arrest since 
p21CIP1 inhibit cyclin E and A-dependent kinase complexes. The activation of p19ARF 
/p53 pathway is associated with telomere dysfunction, oncogene ras activation and 
DNA damage. p53 is vital to DNA damage response signaling pathways (Wahl and 
Carr, 2001) and it is believed that the shortening of telomeres resemble damaged 
DNA, thus triggering a p53-mediated response. The effects of p53 activation in 
senescence may well be an indirect response to the many pathways it regulates. In ras-
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induced senescence, p53 activation was postulated to be caused by the DNA-
damaging effects of ROS production, created from ras-induced MAPK signaling 
(reviewed in Campisi, 2005). Unlike Rb-mediated senescence, p53-mediated 
senescence is reversible, as inactivating p53 in replicative senescent human cells can 
completely reverse the senescent growth arrest phenotype (Gire and Wynford-
Thomas, 1998). 
 
In the Rb pathway, p16INK4a is the key mediator in controlling cell cycle arrest by 
inhibiting cyclin-dependent kinases, which consist of a catalytic subunit (cdk) and a 
regulatory subunit (cyclin). The steps of Rb activation begins with p16INK4a induction 
upon stress stimuli, which in turn bind to cdk4/6 to inactivate cdk4/6-cyclinD 
complexes via inhibition of ATP binding and thus displacing cyclinD. Consequently 
the Rb proteins remain hypophosphorylated, leading to G1 arrest, as cdk4/6-cyclinD 
complexes are required for Rb phosphorylation during G1-S transition (Serrano et al, 
1993). This inactivation of Rb also lifts its repression of E2F transcription factors, 
which are responsible for promoting cell proliferation (Stevaux and Dyson, 2002). 
p16INK4a activation comes mainly from conditions of cellular stress, such as genotoxic 
and oxidative stress, as well as ras overexpression. The activation of this pathway is 
irreversible, as once pRb is engaged by p16INK4a, the senescence-mediated growth 
arrest cannot be reversed by subsequent p53 inactivation, silencing of p16INK4a, or 
inactivation of pRb (Beausejour et al., 2003). Therefore the p16INK4a/Rb pathway may 
function as a final barrier to cell proliferation, in situations where senescence can be 
overcome by p53 loss or inactivation (Campisi, 2005).  
 
The activation of either pathway appears to depend on the type and species of origin 









Fig 1.3. The two major pathways of senescence, the p16INK4a /Rb and p19ARF /p53 
signaling pathways. Activation by various stimuli, and the key molecules involved in 
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p16INK4a appears to be essential for senescence of human cells since fibroblasts 
carrying inactivating mutations of p16INK4a can be resistant to ras-induced senescence 
(Carnero et al., 2000, Huot et al., 2002). The p16INK4a /Rb pathway was also found to 
be important for melanocyte senescence, melanoma progression (Bennett, 2003). 
These pathways may cooperate to regulate senescence, as seen with Pak4 bridging 
p16/p19 pathways through MAPK-ERK (Cammarano et al., 2005), while the 
inactivation of both pathways can bypass senescence and trigger cell transformation 
(Hara et al., 1991). 
 
 
1.2.3.2 p16INK4a , a biomarker of aging 
   
 
The INK4 family of proteins regulates cell cycle progression by binding and 
inhibiting cdks. p16INK4a belongs to this family that also includes p15INK4b, p18INK4c 
and p19INK4d/ARF. p16INK4a and p19ARF are alternative splice variants from the INK4a 
locus, and therefore they are not isoforms and share no homology in amino acid 
sequence (Kim and Sharpless, 2006). Three p16INK4a variants have been found to exist 
in senescent human fibroblasts (Weebadda et al., 2005). 
 
p16INK4a arrest cells at the G1 phase of cell cycle, and the induction of p16INK4a in 
normal proliferating cells is a relatively rare event (Serrano et al, 1993). Instead, 
p16INK4a expression is normally silenced by methylation in cultured cells as well as in 
vivo (Holst et al., 2003). p16INK4a have been established to be a true biomarker of 
mammalian aging, as its in vivo expression correlates with the aging of mice 
(Krishnamurthy et al., 2004). Moreover, the increasing p16INK4a gene dosage (to lesser 
extent with p19ARF) results in normal aging and resistance to cancer (Matheu et al., 
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2004). More recently, p16INK4a was found to promote the age-dependent decrease in 
proliferation and self-renewal capacity of progenitor cells in different organs such as 
brain, bone marrow and pancreatic islets (Molofsky et al., 2006, Janzen et al., 2006 
and Krishnamurthy et al., 2006).   
 
Among cdk inhibitors, p16INK4a is the only known bona fide tumor suppressor, since 
p16INK4a function, or its downstream mediators is frequently de-regulated in many 
types of human cancers (Okamoto et al., 1994). Therefore, p16INK4a and the p16INK4a –
pRb pathway remains a molecular link between cellular senescence and tumor 
suppression (Ohtani et al., 2004). 
 
Some progress has been made in understanding the regulation and kinetics of 
p16INK4a. The stable expression of p16INK4a during replicative senescence was a result 
of decreased p16INK4a mRNA turnover, mediated by a mRNA decay protein AUF1 
(Wang et al., 2005). p16INK4a was also demonstrated to participate in epigenetic 
regulation, as high-mobility group A (HMGA) proteins cooperate with p16INK4a to 
promote senescence-associated heterochromatin foci formation, thus stabilize 
senescence by silencing E2F target genes (Narita et al., 2006). 
 
1.2.3.3 Biochemical markers of aging 
 
 
To date, current research employs a limited set of candidate markers to define and 
measure the degree of senescence.  Key genes are cell cycle inhibitors p16INK4a and 
p19ARF (ARF), where their mRNA expression markedly increases with aging. The 
expression profile of p16INK4a often correlates with the up-regulation of enzyme SA--
Gal (Senescence-associated--Galactosidase), which remains the gold standard for 
detecting senescence in vitro and in vivo (Dimri et al., 1995). Interestingly, the 
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discovery of senescence-associated heterochromatic foci (SAHF), which accumulates 
in senescent human fibroblasts, may serve as a potential marker. The formation of 
SAHF was found to correlate with stable repression of E2F target genes, validating 
the existence of an intact p16-Rb mediated senescent pathway (Narita et al., 2003). 
 
 
1.2.4 Progeroid syndromes  
 
 
Does senescence reflect aging in humans? Although the features and causative agents 
of aging vary widely among species, some universal aging mechanisms have been 
identified, such as alterations to insulin-IGF axis. Yet, mechanisms primary to aging 
in humans may not necessarily have counterparts in every metazoan (Kipling et al., 
2004). The study of aging in humans are modeled on progeroid (premature aging-like) 
syndromes, which are human genetic diseases with outcomes that mimic aging 
phenotypes (Martin, 1985). However, most progeroid syndromes manifest only partial 
aging phenotypes, which compound the fear that these syndromes may have resulted 
from mechanisms postulated to play only causal roles in normal aging (Hasty et al., 
2003). 
 
Genomic instability remains a fundamental problem as defects in genome 
maintenance can greatly compromise survival and accelerate aging. In humans, 
Werner syndrome (WS) displays severe age-related diseases such as type II diabetes, 
osteoporosis and calcification of cardiac valves, arising from DNA helicase (RecQ) 
mutation. The ataxia telangiectasia (ATM) syndrome, which exhibits 
immunodeficiency and osteopenia (Hishiya et al., 2005), arises from defects in repair 
of double strand breaks (reviewed in Lombard et al., 2005). Hutchinson-Gilford 
progeria (HGP), shows distinct tissue specific features, due to mutations in lamin A/C 
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(Goldman et al., 2004). A common ground for comparative studies between humans 
and mice have been achieved by crossing the Werner gene (wrn) to telomerase-null 













































1.3 Bone development & pathophysiology   
 
The physiological functions of bone serve not only as a support system for our 
internal organs, but also for body movement, body resistance and adaptation to 
changing mechanical stress/loading. Other essential roles for bone lie in the regulating 
homeostasis of ions; in particularly calcium, as well as providing the site for 




1.3.1 Bone tissue and the process of osteogenesis 
 
 
The skeletal system consists mainly of bone tissue, a specialized form of connective 
tissue with its extracellular matrix (ECM) components calcified. Mineralization 
confers immense rigidity and tensile strength, characteristics of bone. The average 
compact bone holds 30% organic matrix and 70% salts in which collagen fibers fill 
the organic matrix and the gradual deposition of inorganic bone salts (mostly calcium 
and phosphates which forms hydroxyapatite crystals) increases its compressional 
strength, along with tensile strength, to create a material reminiscent of reinforced 
concrete (Guyton and Hall, 1996). Anatomically, bone is comprised of 2 different 
types of structures, namely the compact bone (cortical bone), which is the outer hard 
shell that forms the shaft of long bones, and spongy bone (trabecular/cancellous 
bone), which consists of a lattice-like network of bony spicules with interconnecting 
spaces filled with bone marrow cells (Burkitt et al., 1999).  
 
During development, immature woven bone can be found in a developing embryo, up 
to childhood before 14 years of age, and temporarily in the regions of bone 
undergoing repair. Over time, secondary bone takes over to form well organized 
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lamellar bone, which contains compact and cancellous bone, forming the mature 
skeleton. The process of endochondral ossification takes place in all long bones. 
Unlike intramembraneous bone formation (which involves direct bone formation 
within primitive connective tissue), this process requires the development of a 
cartilage platform prior to bone formation, and an intricate network of several cell 
types. Long bone growth involves expansion of bones in diameter and length. The 
increase in thickness of cortical bone shaft (diaphysis region) can be achieved by bone 
deposition on the periosteal surface, and resorption at the endosteal surface that 
begins from the center region of bone and creates a hollow bone marrow cavity. On 
the other hand, an increase of bone length takes place primarily at the ends of long 
bones, termed epiphyseal plate region (growth plate). It is the fusion of epiphyses 
which results in the loss of growth plates and hence cessation of bone growth at the 
end of adolescence (www.techion.ac.il).   
 
At the cellular level, 3 major cell lineages originating from mesenchymal stem cells 
critical to osteogenesis are osteoblasts, osteoclasts and chondrocytes. Endochondral 
ossification of long bones begins with condensation of mesenchymal cells to form 
chondrocytes (Kronenberg, 2003), laying down a hyaline cartilage template which 
then directs the differentiation of osteoblasts to form mature bone (Russell et al, 
2006). Osteoclasts act to remove bone, while osteoblasts function to form new bone. 
 
1.3.2 Bone remodeling 
 
 
As progression of early bone modeling to formation of mature skeleton is completed, 
the complicated process of bone remodeling begins. Continuous bone remodeling 
takes place so as to maintain bone homeostasis, bone architecture and buffer 
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circulating plasma calcium in the body. Bone remodeling involves creating new bone 
tissue in place of old bone, and these require the orchestrated actions of osteoblasts 
and osteoclasts, to form a basic multicellular unit (BMU).  
 
A cycle of BMU action revolves around 3 consecutive phases: bone resorption, 
reversal and formation. Osteoclasts, multinucleate cells derived from the 
monocytic/macrophage lineage, resorb bone upon migration to the bone surface, 
leaving open ‘trenches’ or cavities that are 20-40m deep in cortical bones. This 
resorption stage is then followed by a reversal phase with mononuclear cells 
appearing on bone surface, to prepare the surface for new bone by signaling for the 
maturation of osteoblast progenitors and subsequently recruiting osteoblasts to the site 
to lay down new bone till the resorbed site is fully covered, completing the final phase 
of the cycle. Flattened lining cells then occupy the site until a new remodeling cycle is 
initiated. This process is illustrated in Figure 1.4.  
 
Hence, the actions of osteoblasts and osteoclasts are closely coupled to each other. 
Bone turnover occurs more actively in trabecular bones, which form 20% of skeletal 
mass but holds 80% of total bone surface due to the larger surface to volume ratio. 
Nevertheless, up to 2-5% of cortical bones, and about 25% of trabecular bones are 
replaced annually during adulthood (Hadjidakis and Androulakis, 2006, Manolagas 
and Jilka, 1995). Bone remodeling is regulated by a numerous factors, which range 
from secondary/systemic influence via the endocrine system (such as parathyroid 
hormone (PTH) and estrogens), to local regulation in the bone microenvironment via 
the release of cytokines that regulate osteclasts (osteoprotegerin-OPG), or osteoblasts 











Figure 1.4. The process of bone remodeling in normal bones carried out by 
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1.3.3 Osteoblast biology  
 
 
Osteoblasts form new bone by first synthesizing complex extracellular matrix 
including collagen fibres (termed osteoid), which is then subsequently mineralized. 
Osteoblasts are found in clusters, lining the layer of bone matrix that they are 
producing on the bone surface. When its matrix secreting period ceases, 15% of 
mature osteoblasts become entrapped in the new bone matrix and differentiate into 
osteocytes, while some remain on the bone surface to form flat lining cells 
(Hadjidakis and Androulakis, 2006). Such functions require osteoblasts to be rich in 
the enzyme alkaline phosphatase that is needed for the formation of the mineral 
deposits in the matrix. Due to the metabolic requirements of this cell type, it is also 
morphologically a large cell filled with abundant basophilic cytoplasm that holds a 
huge Golgi apparatus, a pale stained nucleus but prominent nucleolus, features that 
reflect a high rate of protein and proteoglycan synthesis (Burkitt et al., 1999). 
 
 
1.3.3.1 Osteoblast differentiation and proliferation 
 
 
Cells of the osteoblast lineage originate from stromal cells of bone marrow, where 
mesenchymal stem cells reside. The pluripotency of these stem cells can give rise to 
not only osteoblasts, but also adipocytes, chondrocytes, myoblasts or fibroblasts 
(Bianco et al 2001). Fibroblast colony-forming unit (CFU-F) remains the earliest cell  
to commit to the osteoblast lineage (Manolagas and Jilka, 1995).  The commitment of 
precursor cells to the osteoblastic fate involves the complicated coordination of 
several cytokines and growth factors, and timed expression of osteoblast specific 
transcription factors. Figure 1.5 illustrates the stages of osteoblast differentiation, 
along with the biochemical markers that are expressed by osteoblasts at different 
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phases of differentiation. The early steps of cell commitment to preosteoblast remains 
vague, but several factors have been singled out in driving proliferation and expansion 
of precursor osteoblasts, and they include bone morphogenetic proteins (BMPs), 
fibroblast growth factor (FGF), insulin-like growth factors I and II (IGF-I and IGF-II), 
platelet-derived growth factor (PDGF) and transforming growth factors-1 and 2 
(Mundy et al., 2001, Chen et al, 2004), though most of these factors act to exert 
similar effects on mesenchymal cells in general. Moreover, the differentiation 
program of osteoblast is dependent on the expression of master genes Runx2 (or core 
binding factor 1/cbfa1), and osterix (osx). Through genetic studies it was found that 
both transcription factors are essential in bone formation as Runx2 null mice form a 
skeleton made entirely of cartilage and not normal bones (Ducy et al., 1997, Komori 
et al., 1997), while Osx-/- mice do not develop bones. It was believed that osterix 
worked downstream of Runx2 as Runx2-/- mice do not express osterix at all, while 
Runx2 was expressed in Osx-/- mice despite the lack of bone formation(Nakashima et 
al., 2002). Other transcription factors than influence osteoblast differentiation in vivo 
include the homeobox proteins Dlx5, Dlx6 and Msx2 (reviewed in Ducy et al., 2000). 
More work remains to be done on uncovering the regulation of osteoblast 
differentiation, in comparison to the extensive research and knowledge obtained about 
osteoclast biology. 
 
1.3.3.2 Signaling pathways in osteoblasts 
 
 
The signal transduction pathways that occur in osteoblasts can be traced from the 





















































Figure 1.5. The various stages of cell fate commitment to osteoblast differentiation. Growth factors and cytokines (in green) are placed from the 




importance to osteoblasts as the transcription of key genes Runx2 and osterix are 
dependent on it. Activation of these 2 master genes drives the terminal differentiation 
of osteoblasts, by enhancing osteoblast specific genes such as alkaline phosphatase 
and osteocalcein. In addition, other growth factors may act to complement or 
antagonize BMP signaling. TGF can also induce Runx2 expression via activated 
effectors Smad2 and Smad3 (Lee et al., 2000). Growth factors FGF, IGF-1, and 
endothelin-1 (ET1) activate osteoblast MAPK (mitogen activated protein kinase) 
cascade via transmembrane or G-protein coupled receptors. These activated pathways 
can also ultimately lead to Runx2 and osterix gene regulation, via other kinases such 
as protein kinase C (PKC) in the case of FGF signaling (Kim et al., 2003). Also of 
importance is the canonical Wnt signaling pathway, whereby co-receptor LRP5 was 
shown to be involved in bone formation (Boyden et al., 2002), independent of Runx2 
(Kato et al., 2002), while -catenin was also required for osterix expression (Rodda 
and McMahon, 2006). Notably, the most well studied connection between osteoblasts 
and osteoclasts comes from the RANKL-RANK-OPG interaction that show 
osteoclasts need osteoblast secreted RANKL (receptor activator of nuclear factor 
kappa-B ligand) to mature (Russell et al., 2006).  
 
Of newer interest is osteoblast apoptosis, where the activation of apoptotic pathways 
may be part of osteoblast signaling since bone cells may undergo programmed cell 
death to control life span, affecting changes in bone turnover as well (Manolagas, 
2000). Proapoptotic proteins Bim, Bak and Bax were found to be induced in 
osteoblasts via the caspase 3 pathway upon serum deprivation (Liang et al., 2008). 
Nevertheless, the multiple pathways an osteoblast can support due to the abundance 
of growth factors it secrete can also be a bane as in the case of frequent metastatic 
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secondary tumors of bone developed from primary adenocarcinomas, through 
stimulation of osteoblast proliferation (Logothetis and Lin, 2005). 
 
  
1.3.4 Disorders of bone remodeling 
 
 
In healthy adults, bone turnover is maintained at a steady state as the rate of resorption 
roughly equals the rate of bone deposition. Disorders of bone remodeling occur as a 
result of an imbalance in these two actions. Osteoporosis develops when the rate of 
bone resorption exceeds the rate of bone formation, such that resorption cavities left 
by osteoclasts are incompletely replaced by new bone, creating perforations in bone 
structure. Less common is osteopetrosis, characterized by high bone mass 
(osteosclerosis) due to the higher bone formation rates, the opposite outcome of the 
former (Russell et al., 2006, Lazner et al., 1999) 
 
The cellular mechanism behind bone disorders is not completely understood; as the 
understanding on bone remodeling remains vague.  Bone remodeling is a continuous 
process with each phase requiring different time frames; resorption takes about 2 
weeks in contrast with bone formation needing up to 4 months for complete structural 
bone replacement (Hadjidakis and Androulakis, 2006).  
 
 
1.3.4.1 Osteoporosis, a disease of low bone turnover  
 
 
Osteoporosis/osteopenia is a disease characterized by low bone mass. The most 
common and widespread bone disease, osteoporosis affects mainly the older 
population with a higher incidence in women.  
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One of the two primary causes is loss of gonadal function/estrogen deficiency termed 
postmenopausal bone loss, which is usually rapid.  The other is gradual bone loss with 
aging (non-hormonal), in which both causes are known to operate through 
independent mechanisms. Bone loss through aging differs from hormonal deficiency 
as bone formation decreases over time, due to a progressive decline of osteoblasts 
supply relative to the demand. This “exhaustion” or senescence of precursor cell 
population in the marrow results in irreversible loss of bone mass over time, usually 
affecting cortical bones. Post-menopausal osteoporosis, on the other hand, is 
effectively the result of excessive osteoclast activity that mainly affects trabecular 
bones (Manolagas and Jilka, 1995). 
 
Age-related bone loss is also termed as senile osteoporosis. The major sources of 
senile osteoporosis stem from either systemic abnormality, or osteoblast dysfunction. 
Systemic influences include insufficient active vitamin D. Intrinsic osteoblast 
dysfunction results from factors found in the osteoblast or surrounding it (within its 
microenvironment). The local microenvironment of the osteoblast is controlled by 
cytokines and growth factors such as BMPs and IGF-1, though none of these factors 
can solely be responsible for the etiology of aging-associated bone loss (Kawaguchi, 
2006). 
 
Therefore, what causes senile osteoporosis? Several genetic and systemic factors have 
been implicated, in an attempt to uncover its pathophysiology. Osteoporosis is 
generally known to be a multiple-factor disease and is believed that genetic 
susceptibility plays substantial role at an early age. Despite no single gene have been 
identified to be directly the sole cause of osteoporosis, linkage studies have identified 
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several loci that may contain the genes regulating bone mineral density (BMD), which 
can alter one’s risk to disease progression (Russell et al., 2006). One such example of 
genetic impact is the role of Sca1 gene, present on a subset of bone marrow stroma 
whereby Sca1-/- mice born with normal bone development matures to senile 
osteoporosis with age, due to the deficiency in self-renewal capacity of mesenchymal 
progenitors (Bonyadi et al., 2003).  
 
The increased risk for fractures and the lack of promising therapeutics remains the 
major concerns about osteoporosis (reviewed in Canalis et al., 2007). Current drugs 
are created as pre or post-therapeutics. Anti-resorptive drugs include oestrogens, 
bisphosphonates and selective estrogen receptor modulators (SERMs). The next class 
of therapeutics is anabolic drugs, targeted to promote bone formation and these 
include PTH/teriparatide and strontium (reviewed in Russell et al., 2006). More 
promising osteoblast-promoting drugs may be in the pipeline to enhance bone 
formation. Local administration of rhIGF-1 could significantly induce new bone 
formation in the already impaired bone formation ability of aged mice, hence rhIGF-1 
may improve senile osteoporosis (Fowlkes et al., 2006). Also, small-molecule PYK2 
(proline rich tyrosine kinase 2) inhibitor was targeted as a promising anabolic 
approach to regulate osteoprogenitor differentiation (Buckbinder et al., 2007).  
 
 
1.3.4.2 Mouse models of senile osteoporosis 
 
 
Senile osteoporosis is difficult to study as it develops slowly, and despite the advances 
in human and mouse genetics, skeletal physiology remains poorly understood. To 
date, a database of over 120 bone-related mouse models have been archived to close 
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the gaps on understanding bone biology. Transgenic and mutant mice remain the most 
appropriate genetic tools to dissect bone disease (Pogoda et al., 2005). 
 
Notably, much of aging-related research came from the SAM (senescence–accelerated 
mouse) family of mice. In as early as 1970s, Takeda and team, through selective 
inbreeding of AKR/J strain mice that exhibited natural spontaneous senescence and 
aging-like features, developed 14 senescence-prone inbred strains and 4 senescence-
resistant inbred strains (SAMR) as control counterparts that show normal aging 
(Takeda, 1999). In particular, the SAMP6 strain developed distinct senile osteoporotic 
features, and was subsequently used as a model to study the basis behind aging-
associated osteoporosis (Matsushita et al., 1986). Research on SAMP6/Ta uncovered 
the depletion of osteoblast progenitor pool as a result of bone marrow tendency to 
favor adipocyte differentiation, rather than osteoblasts (Suda et al., 1994). Also, it was 
found that the initial healthy numbers of bone marrow osteoprogenitor cells at 1 
month of age deteriorated to a palpable 3-fold reduction by the 3rd to 4th month of 
SAMP6 lifespan (Jilka et al., 1996). Hence it is highly probable that the switch in the 
differentiation program of multipotential mesenchymal progenitors is one such basis 
for senile osteoporosis, as osteoblasts and adipocytes share the same progenitor. 
Using the SAMP6 mice, Takeda and team was able to treat senile osteoporosis by a 
novel surgical method of bone marrow transplant and normalize the defective bone 
marrow constituents (Takada et al., 2006). 
 
More current genetic approaches to understand senile osteoporosis come from mouse 
models focused on systemic influences of bone metabolism. Circulating levels of 
IGF-1 could regulate bone growth and density (Yakar et al., 2002) and is involved in 
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the pathophysiology of osteoporosis via IRS (insulin receptor substrates). IGF-1 
signaling requires the essential adaptor molecule IRS to activate PI3K/AKT and 
MAPK pathways (Kadowaki et al., 1996).  The low bone turnover of IRS-1-/- revealed 
its essential role in promoting catabolic and anabolic osteoblast functions (Ogata et 
al., 2000), while decreased bone formation and increased bone resorption rate of IRS-
2-/- revealed an uncoupling status that has to be fine-tuned by IRS-2 (Akune et al., 
2002). In addition, PPAR+/- mice exhibited high bone mass by stimulating 
osteoblastogenesis from bone marrow progenitors, increasingly prominent with age. 
Hence, heterozygote mutation of PPAR, a key regulator of adipocyte differentiation 
and a factor intrinsic to osteoblasts, shows the fundamental relationship between 
osteoblasts and adipocytes in the regulation of osteoprogenitor population 
(Kawaguchi, 2006). Another interesting example of systemic impact on osteopenia 
comes from the klotho homozygous null (kl/kl) mice that exhibit age-related bone loss 
and independent impairment of osteoblast and osteoclast differentiation (Kawaguchi 
et al., 1999). These 3 newer players depict the coupling of bone metabolism with 
bone aging. The role of ECM proteins in osteoporosis was also explored with the 
study on non-collagenous ECM protein biglycan (Bgn), whereby Bgn-/- mice 
developed osteoporotic-like phenotypes (Xu et al., 1998).
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1.4 Bone morphogenetic proteins   
 
 
The bone morphogenetic proteins (BMPs) belong to the transforming growth factor 
(TGF) superfamily of signaling molecules which also consist of TGF, activin and 
inhibin (Wozney, 1988). BMPs were first discovered to induce ectopic bone 
formation when implanted into rodents, and subsequently established an ability to 
drive undifferentiated stem cells into the osteogenic program (Urist, 1965). The early 
developmental stages of patterning and organogenesis were found to be regulated by 
BMPs, and due to its pleiotropic actions it is also involved in adult tissue homeostasis 
Hogan, 1996). 
 
BMPs proteins have seven cysteine residues (conserved in TGF superfamily), and 
are first synthesized as large precursors that require proteolytic cleaving to release its 
active C-terminal domain. BMPs can then be secreted as mature, dimeric ligands of 
20 – 30 kDa in size. Over 20 distinct BMPs have been isolated. In vivo bone 
promoting BMPs are BMP2, 4, -6 and -7(Osteopontin-1) and -9.  Of these, BMP2 and 
BMP4 remains the foremost well characterized members with potent osteoinductive 
activities, and has been developed for orthopedic clinical applications in animal 
models (reviewed in Chen et al, 2004). The essential roles of BMP2 and BMP4 in 
development were validated by the observed embryonic lethality of bmp2-/- mice with 
cardiac defects (E7.5-10.5) and bmp4-/- mice with defects in mesoderm formation 









1.4.1 BMP-Smad pathway 
 
 
The canonical BMP pathway consists of a signaling cascade mediated by 
serine/threonine (S/T) kinase molecules. The step-wise activation of downstream 
molecules requires S/T phosphorylation. Figure 1.6 describes the various signal 
mediators involved. BMP signaling begins at the plasma membrane, with BMP ligand 
binding to type I and II BMP receptors, inducing heterodimerization of these 
receptors. This activates the BMP type II (BMPRII) receptors, which in turn 
phosphorylates Type I receptors (BMPRI) at its unique GS domain. Upon GS box 
activation, BMPRIs becomes activated by autophosphorylation and recruits the next 
step of transducers, the Smads. BMP-Smads (Smads1/5/8) are then activated and form 
hetero-trimeric complexes with Smad4 (a common Smad shared by all TGF 
superfamily members), to translocate into the nucleus and activate the transcription of 
target genes (Massague, 2000). Figure 1.7 illustrates the BMP signaling pathway and 
the modulators at different compartments of the cell. 
 
 
In the TGF superfamily, there are 5 type II receptors and only BMPRII specifically 
binds to BMP. 7 type I receptors exist, and BMPRIA (ALK3) and BMPRIB (ALK6) 
are specific for BMPs, The basic structure for BMP receptors are modeled on TGF 
receptors, seen in Figure 1.8.  Both type I and type II consist of a short extracellular 
domain, a transmembrane domain and a large intracellular S/T kinase domain. Type I 
receptors contain a serine-glycine rich domain (GS box) at the N-terminal region prior 
to kinase domain, which is needed for activation by BMPRII (Massague et al., 1994, 
Shi and Massague, 2003). BMPRII has an extremely long C-terminal tail, which was 
















Fig. 1.6. The TGF superfamily of signaling molecules. Step-wise activation of 
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Fig 1.7. The canonical BMP-Smad pathway and signaling modulators. Negative 
regulators exist at the extracellular and cytoplasmic compartments (green boxes), and 
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Fig 1.8.  The basic structures of BMP type I and type II S/T kinase receptors. 
Common to these two classes of receptors are the extracellular domain, a single 


























BMPRIA is a 55 kDa protein that is ubiquitously expressed in most cell types 
including osteoblasts, and in cultured cells COS7 and osteoblastic cell line MC3T3. 
This was also the case for BMPRII, a 70-80 kDa protein, which was highly expressed 
in most tissues, while BMPRIB expression was confined to limited tissues such as 
glioblastomas. Core BMP signal transduction appears to mediated by BMPR1A and 
BMPRII rather than BMPRIB, as bmpr1a-/- embryos die at E9.5 with no mesoderm 
formation (Mishina et al., 1995), and BMPRII null mice is also embryonic lethal 
(Beppu et al., 2000). On the other hand, mice lacking BMPRIB are viable, albeit with 
defects in cartilage formation (Yi et al., 2000). Even though BMPRIA can bind to 
BMP ligands in the absence of BMPRII, its binding affinity is facilitated by the 
presence of BMPRII (Massague, 1996, Kawabata et al, 1998).  
 
Smads are the only known direct effectors of the BMP pathway. There are 8 
mammalian Smads, and these intracellular BMPR substrates are grouped into three 
classes, the receptor-Smads (R-Smads, Smads1/5/8), which confers specificity in 
transcriptional response, the common Smad (co-Smad, or Smad4), which serves as an 
adaptor for R-Smads, and lastly the inhibitory Smads (Smad6/7), which are discussed 
in section 1.4.2. R-Smads and Co-Smad contains the conserved MH1 and MH2 
domains, bridged by a linker region, while the MH1 domain is missing in I-Smads. 
The linker region of Smads have been found to be important for functional regulation 
by other S/T kinases,. More importantly, the C-terminal tail extending out of the MH2 
domain contains the site for BMP receptor activation of Smads. The SXS (Ser-X-Ser) 
motif is only found in R-smads and increases its affinity for Smad4 when activated 
(reviewed in Massague et al, 2000, Miyazono et al., 2001).  
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BMP signaling is complicated by the crosstalk or convergence of BMP signaling 
pathway with other pathways. Pathways known to crosstalk with BMPs include the 
JAK-STAT, Wnt, MAPKs, PI3K/AKT and TGF pathways (reviewed in Bubnoff and 
Cho, 2001). Specificity is highly dependent on cell type contexts. In neural induction, 
the IGF and FGF works in tandem to counter BMP signals, targeting activated Smad1 
(Pera et al., 2003). Moreover, non-canonical Smad-independent pathways exist, and 
may operate in synergy or function to oppose BMP-Smads pathway. For example, 
PKC and MAPKs could be activated by BMPs (Hay et al., 2001, Miyazono et al., 
2005).   
 
Deletion of genes of individual BMP signaling molecules in mice have often led to 
embryonic lethality, due to the key roles they play in embryogenesis. However, in 
humans, several inherited diseases were found to be linked to natural occurring 
mutations in the BMP pathway. In FOP (Fibrodysplasia ossificans progressiva), a 
disabling genetic disorder that promotes aggressive bone growth, ectopic BMP4 was 
found in patients (Gannon et al., 1997). Mutations in Smad 4 were linked to familial 
juvenile polypopsis, and mutations in BMPRII were implicated in a rare autosomal 
dominant disorder, familial primary pulmonary hypertension (Lane et al., 2000, Deng 
et al., 2000). 
 
 
1.4.2 Modulators of BMP signaling pathway  
 
 
Many regulators exist to ensure BMP signaling can be turned off, fine-tuned or is cell 
type specific. BMP signaling modulators discussed here are categorized according to 
their cellular localization: extracellular, cytoplasmic and nuclear.  
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At the extracellular membrane region, BMP antagonists function to block the binding 
of BMP ligand to its cognitive receptors. BMP antagonists behave in a similar fashion 
to BMPs as they share the cysteine-knot structure and originate as a secretary signal 
peptide. The three sub-families of BMP antagonists are based on their cysteine-knot 
size (Avsian-Kretchmer and Hsueh, 2004) and they are the DAN family (e.g. gremlin, 
sclerostin and USAG-1), twisted gastrulation (Tg), and chordin/noggin (reviewed in 
Yanagita, 2005). Of interest are the noggin/chordin family that have been studied in 
depth, due to their importance in regulating bone formation and turnover. Noggin is a 
32 kDa secreted glycoprotein that binds to BMP2 and BMP4 with high affinity and 
BMP7 with low affinity. Noggin gene was found to be induced by BMP themselves, 
which reveals the likelihood that noggin could function as a direct and efficient 
antagonist, and plays a major role in autonomous BMP-signal regulation. The lack of 
noggin function is deleterious, as noggin homozygous null mice had excess cartilage 
and present with a failure to initiate joint formation (Brunet et al., 1998). In humans, 
heterozygous mutations cause apical joint fusions, exhibiting noggin 
haploinsufficiency (Gong et al., 1999). Also, transgenic mice with targeted 
overexpression of noggin in osteoblasts became osteoporotic (Wu et al., 2003). 
Hence, noggin appears to regulate postnatal bone homeostasis as well. Chordin, 
another antagonist found in the Spemann organizer, is a large protein of 120 kDa 
containing 4 cysteine rich domains (Piccolo et al., 1996). It only binds specifically to 
BMP2 and BMP4. Mice deficient for chordin display early lethality and a ventralized 
gastrulation phenotype (Bachiller et al., 2003). Furthermore, double knockout mice 
for noggin/chordin exhibit severe defects in facial structures, head development, 
partial mesoderm development and abnormal left to right patterning (Bachiller et al., 
2000). BMP receptors can also be targeted. BAMBI is a transmembrane protein 
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structurally related to type I receptors, but lacks the serine/theonine kinase domain, 
thus function as a pseudo-receptor to suppress BMP signaling (Onichtchouk et al., 
1999). Dullard, a neural gene, could bind and abolish BMP-mediated activation of 
type I receptors. More importantly, it promoted BMP receptor internalization and 
ubiquitin-mediated proteosomal degradation via the lipid-raft caveolar pathway 
(Satow et al., 2006). 
In the cytoplasm, direct negative mediators of Smad signaling are the third class of 
Smads, the inhibitory smads I-Smad6 and I-Smad7. Smad6 binds to BMP type I 
receptors to inhibit activation of Smad1 and Smad5 and consequently prevent 
heteromerization with Smad4, terminating Smad signaling upstream of receptor 
Smads.  Smad 6 is a BMP target gene and thus participates in BMP signaling 
feedback. Smad7 is less specific as it can also inhibit TGF/activin signaling 
(reviewed in Miyazono et al., 2005). Other regulators of Smad proteins are also 
required. In osteoblasts, anti-proliferation protein Tob (transducer of ErbB2) 
associates with Smad1 and Smad5 to inhibit BMP-Smad dependent transcription, 
while Tob knockout mice displays osteosclerotic phenotype, with increased bone 
mass in adulthood (Yoshida et al., 2000). Smurfs are members of the HECT type E3 
ligases that mediate the degradation of receptor Smads (Zhu et al., 1999), and 
enhanced bone formation was observed in Smurf1 null mutant mice. Phosphatases of 
Smads are the emerging trend towards understanding Smad regulation. The S/T 
phosphatase PPM1A could dephosphorylate TGF-Smads (Lin et al., 2006), and was 
found to deactivate BMP-Smad1 in vitro and in vivo as well (Duan et al., 2006). 
RNAi-based genetic screening has also identified pyruvate dehydrogenase 
phosphatases (PDP) as BMP specific S/T phosphatases (Chen et al., 2006). 
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In the nucleus, the specificity of BMP response comes into play, with the myriad 
classes of transcription factors/DNA binding proteins that function as co-activators, or 
co-repressors to complex with Smads on BMP target genes. Much of the 
transcriptional regulators is also shared by the TGF family, and perhaps differs in 
response by cell type expression. Transcription factor Runx2, is essential to induce 
genes involved in bone formation. Ski and SnoN interacts with Smads, and are 
transcriptional co-repressors that induce histone deacetylation (Wan and Cao, 2005). 
Co-activator p300/CBP was found to bridge STAT3 and Smad1 and transduce BMP-
LIF-mediated transcription in fetal brain (Nakashima et al., 1999). In addition, small 
C-terminal domain phosphatases were found to act as nuclear Smad phosphatases 
(Knockaert et al., 2006). Nucleoplasmic shuttling adds another level of complexity in 
the modulation of Smad signaling (reviewed by Xu and Massague, 2004).  Smad6 
was found to have a novel function in the nucleus through interaction with co-
repressor CtBP to repress BMP-induced Id1 transcription (Lin et al., 2003). 
 
 
1.4.3 BMP target genes 
 
 
Genes targeted by BMPs regulate transcriptional responses to bone differentiation, 
skeletal patterning and angiogenesis. Conversely, BMPs potently repress genes 
involved in muscle differentiation (such as MyoD and myogenin), since they direct 
the differentiation route of mesenchymal stem cells away from the osteogenic 
program. Genes that are direct targets of BMPs include Id proteins, Dlx5, Tsg, 
Msx1/2, GATA2, Tbx2, collagen, Smad6 and Smad7. Mostly BMP modulators 
themselves, they are rapidly transcribed due to the SBE (Smad binding elements) sites 
found on their promoters. On the other hand, indirect target genes such as osterix and 
osteocalcin require de novo protein synthesis, but are indispensable for BMP mediated 
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functions (Miyazono et al., 2005). The Id proteins remain the most well-characterized 
target genes and are further discussed below. 
 
 
 1.4.3.1 Id proteins  
   
  
Id (inhibitor of differentiation, or inhibitor of DNA binding) proteins are a subclass of 
the basic helix-loop-helix (bHLH) family of transcriptional regulators that are critical 
in development. All HLH proteins contain the E-box consensus motif CANNTG that 
regulate distinct tissue specific gene transcription. Dimerization of HLH proteins is 
required for activation, as the formation of four helix bundles allow its basic region to 
bind DNA (Massari and Murre, 2000). Id proteins are a special subclass of the HLH 
family as they possess the HLH domain but lack the basic DNA binding domain. As a 
result they function as dominant negative regulators by binding to bHLH members 
and abolish dimerization, thus antagonizing transcription as illustrated in Figure 
1.9A. Therefore, BMP-induced Id proteins promote cell proliferation and block 
differentiation programs of many cell types (Norton et al., 1998). Ids are proposed to 
act as molecular “brakes” needed for proper and timed developmental processes 
(Carmeliet, 1999), and when this is breeched, excess Id1 production leads to 
uncontrolled proliferation and possibly cancer, while the loss of Id1 increases the 
likelihood of senescence with p16INK4a up-regulation (reviewed in Yokota and Mori, 
2002, Perk et al., 2005). Id proteins targets not only bHLH transcription factors such 
as E-proteins, but also Ets family members, and Rb. Hence its roles are not limited to 
development, but also in balancing cell proliferation versus survival and senescence 
versus cancer (reviewed by Zebedee and Hara, 2001, Sikder et al., 2003). Figure 
1.9B illustrates Id1 role in senescence. 
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Four mammalian isoforms Id1 to Id4 have been identified, and while they exhibit 
some functional redundancy, each Id protein have been shown to retain unique roles, 
which explains their distinct expression patterns throughout embryogenesis (Jen et al., 
1997). Gene ablation studies on Id proteins reveal the in vivo overlapping functions of 
Id1 and Id3, as each Id1-/- and Id3-/- mice are normal, yet double knockout Id1-/-Id3-/- 
is embryonic lethal. Any other Id combinations of double knockout mice were also 
reported to be non-viable (Ruzinova and Benezra, 2003). Moreover, the essential role 
for Id1 and Id3 in in vivo bone formation was studied using Id1/Id3 heterozygous 
knockout mice (Maeda et al., 2004). 
 
In molecular studies, Id1 is often the candidate BMP target gene analyzed. The Id1 
gene can be rapidly transcribed and translated within 30 mins of BMP induction. This 
efficient responsiveness to BMP is due to distinct SBE motifs found on Id1 promoter 
(Korchynskyi and Ten Dinjke, 2002), facilitated by direct binding of Smad1 and 
Smad4 to promoter as well (Lopez-Rovira et al., 2002). The serum responsiveness of 
Id1 to growth signals are found to be regulated by a complex containing the 



















Fig 1.9. Id1 in diffentiation and cell growth. (A) Mechanism of Id1 in inhibiting 

































1.5 Thesis rationale    
 
 
Since the discovery of c-Abl, there has not been much progress in understanding its 
function, the genes it affects, and the roles it plays in cell signaling networks. The 
establishment of c-Abl knockout mouse provided genetic evidence for its role in 
development and survival. Also, many of the c-Abl-/- phenotypes observed resembled 
aging-related syndromes. 
 
This study was undertaken to investigate the molecular mechanisms behind the 
premature senescence phenotype of c-Abl-/- osteoblasts. c-Abl mice showed reduced 
bone formation rate, thinner cortical bone and lower trabecular bone volume. It was 
found that defects in osteoblast maturation were the underlying causes of its 
osteoporotic feature (Li et al., 2000).     
 
My project employs mainly primary osteoblasts, as well as bone sections to help 
identify the pathways and key mediators involved. In doing so, the ex vivo and in vivo 
results provides a better insight into the understanding of physiological functions of c-
Abl in bone development, bone homeostasis, and how it participates in a signaling 
pathway. The consequences of altered tyrosine kinase activity in the case of BCR-
ABL, and its impact on the BMP signaling pathway are also explored here. 
 
 
This thesis is divided into 9 chapters;  
Chapter 1 contains general literature review to provide background information for 
this project. 
Chapter 2 describes the materials and methods used for this study. 
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Chapter 3 describes the poor growth potential and premature senescence of c-Abl-/- 
osteoblasts through the up-regulation of p16INK4a. 
Chapter 4 identifies the two major regulators of p16INK4a; Id1 and MAPK-ERKs, and 
their expression pattern in c-Abl-/-  osteolasts.   
Chapter 5 examines in detail c-Abl regulation of Id1 expression under the BMP 
pathway, and the positive effect of c-Abl on Smad1/5/8 activation. 
Chapter 6 demonstrates how c-Abl regulates BMP signaling through the 
phosphorylation of BMPR1A, and the mechanism behind compromised Smad 
activation in the absence of c-Abl. 
Chapter 7 deals with the negative effect of c-Abl on BMP-induced ERK activation, 
through its action on BMPR1A. 
Chapter 8 provides another perspective on c-Abl role in osteoprogenitor expansion, 
using the BCR-ABL model to study BMP-Id1- p16INK4a signaling and the implications 
for CML. The expression of p16INK4a in bone marrow cells relative to age was also 
explored. 























MATERIALS AND METHODS 
 
 
2.1 Chemicals and antibodies   
 
Table 2.1 List of antibodies used 
 






















HA affinity matrix Monoclonal/ rat Roche 
Flag-M2 affinity gel 
Actin Monoclonal/ mouse Sigma 
BMPRII 
BMPRIA Polyclonal/ goat R & D Systems 
BMPRIA 
BMPRIB Polyclonal/rabbit Zymed/Invitrogen 
c-Abl (Ab-3)  
Smad1 
Monoclonal/mouse 
Polyclonal/ rabbit Oncogene/Calbiochem 
p-Tyrosine (PY20) Monoclonal/mouse BD Transduction Laboratories 
 
 
For drugs and chemicals used, rhBMP2 was obtained from iDNA, rmNoggin and 
rmChordin from R&D Systems, hygromycin-B from Invivogen, puromycin 
dihydrochloride from USBiological, sequabreene from Sigma, U0126S from Promega 
and Imatinib mesylate/STi571 from Norvartis, tunnel assay kit and BrdU labeling 
reagent from Roche. Formulations and chemical/drug preparations can be found in 
Appendix E. 
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2.2. Cell culture 
Adherent cell lines C2C12, cos7, c-Abl-/- and c-Abl-/- Arg-/- mouse embryonic 
fibroblasts were cultured using Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma). Suspension cells HL60 and K562 were cultured using RPMI-1640 media 
(Sigma). MC3T3E1 and c-Abl-/- or wild type primary osteoblasts were cultured in 
Minimal Essential Medium Alpha (αMEM, Gibco), with 15% FBS for osteoblasts. 
All media were supplemented (otherwise stated) with 4.5g/L glucose, 2mM L-
glutamine (Gibco), 10% (v/v) fetal bovine serum (FBS, Hyclone), anti-mycotic 
antibiotic solution containing 100 units/ml penicillin, 100ug/ml streptomycin and 
250ng/ml amphotericin-B, and 20mM HEPES in a humidified 37oC incubator 
containing 5% CO2.  
 
 
2.3. Cavarial osteoblasts isolation and culture 
c-Abl null mice (abl1) were crossed to C57BL/6 mice six times before use. To extract 
primary osteoblasts, calvaria of 19-20 day old fetuses were harvested, washed in PBS 
before being digested for 10mins with collagenase and dispase (Roche) in αMEM at 
37oC. Digestion was repeated for another 3 times. The supernatant from the first 
digestion was discarded and last 3 digested supernatants pooled. Finally, the cells 
were then washed and plated onto 6-well plates and left to grow in αMEM 
supplemented with 15% FCS until they reach confluency. The pre-osteoblast cultures 
were then trysinized and cell population expanded to passage 3 before being used for 
experiments. c-Abl deficient mice were compared to their control littermates in all 






2.4. Senescence associated-beta-galactosidase (SA-β-Gal) assay   
Cells were washed in TBS buffer, and then fixed in 2% formaldehyde / 0.2% 
glutaradehyde for 3 mins at room temperature. Cells are washed with PBS again, and 
rinsed with H2O to remove fixation solution. Freshly prepared X-Gal staining solution 




2.5. Cell proliferation assays   
The following 2 methods were employed; 
Manual cell counting 
The proliferation potential of the mutant and wild type primary osteoblasts starting 
from passage 3 were used for continuous counting and plating via the trypan-blue dye 
exclusion method.  4x105 cells were plated onto 6 cm dishes, cultured for three days, 
and counted.  The same number of cells were re-plated, cultured for three days and 
counted again.  The procedure was repeated until the cells stopped dividing.   
BrdU incorporation 
Cell proliferation was directly assessed using DNA synthesis as an indicator of 
growth by measuring the incorporation rates of synthetic DNA analogue BrdU (5’-
Bromo-2’-deoxy-uridine) in place of thymidine. The Cell Proliferation Biotrak ELISA 
kit (Amersham Biosciences) was used and apart from following manufacturer’s 
protocol; osteoblasts at various passages were seeded at 3 different densities of 1x103, 
5x103 and 1x104 in 96-well plates, in triplicates. The next day, BrdU labeling was 
carried out and incubated overnight (16 hrs) and the final colorimetric measurement at 




2.6. Infection by retrovirus and selection  
 
Transfection 
Platinum-E cells (PlatE, courtesy of Dr. Kitamura), a modified 293T-derived 
ecotropic packaging cell line, was seeded in a 10 cm2 dish to achieve 80% confluency 
the next morning (refer to Appendix B for PlatE media). 6ug of retroviral plasmid 
harbouring Id1, GFP, p16INK4a, c-Abl or BMPR1A and control empty vector was 
tranfected into PlatE cells overnight using Fugene reagent (Roche). The following 
day, cells were replaced with 8mls of fresh media, and left to incubate for another 48-
72 hrs.  
Infection  
Following incubation, the media supernatant containing matured virus was used to 
infect early passage primary cells. Polybreene (Sequabrene, Sigma) was added (final 
concentration 8ug/ml) to viral supernatant and filter-sterilized prior to infection. Post 
8 hrs infection, fresh media containing polybreene was added to dilute existing 
supernatant at a 1:1 ratio and left for a further 16 hrs. Supernatant was then aspirated 
and cells recovered in fresh media for 24 hrs before starting the selection stage. 
Selection  
24 hrs post recovery, cells were subjected to selection with hygromycin B 
(HygroGold, InvivoGen) or puromycin (US Biological).The selection process was 
monitered daily to observe for cell death, so as to optimize drug dose till a ~30-40% 
cell death rate was achieved, and after 3-7 days in selection (with selection drug 
changed every 3 days), resistant cells were further passaged and seeded for various 






2.7. Bone marrow extraction 
 
Mice were sacrificed using Advertin as anesthesia and hindlegs removed to obtain 
femoral (thigh) and tibia bones. The bones are washed several times with cold PBS 
and trimmed at the edges to reveal the bone marrow. Marrow/stroma was then flushed 
out using DMEM normal media and a syringe. Marrow cells were then spun down in 
a 4oC centrifuge and cell pellet washed several times with cold PBS. Cells were lysed 
with TNEN lysis buffer (for protein), or TRIzol (for RNA extraction). Red blood cells 
were lysed using RBC lysis buffer prior to beginning protein or RNA work. 
 
 
2.8. Transient transfection 
Cells were counted and seeded to achieve 40-50% confluency the next day. 
Transfection was carried out with 3-4ug total DNA per 6 cm2 dish using 
Lipofectamine and Plus reagents (Invitrogen) for cos7 cells and Fugene (Roche) at a 
6:1 ratio for MC3T3 cells, according to manufacturer’s protocols. Cells were 
incubated with transfection complex for an average of 3.5 – 5 hrs (cos7) or overnight 
for MC3T3, before being recovered with fresh complete media for a minimum of 36 
hrs, including serum starvation for the last 16 hrs if necessary. Upon treatment, cells 
were harvested to proceed with western blotting or RNA extraction. 
 
 
2.9. Western blot 
 
Sample preparation 
Harvested cells were lysed on ice and washed twice with cold PBS. TNEN lysis 
buffer (containing 50mM Tris, pH7.5, 100mM KCl, 1mM EDTA, 0.5% NP-40, 1mM 
PMSF, 1mM sodium orthovanadate, 10mM NAF, 1mM -glycerolphosphate and 
10ug/ml each of aprotonin and leupeptin) was then added and lysates left to rock for 
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30 mins at 4oC before spinning down at maximum speed for 10 mins. An aliquot of 
spun supernatant clear of debris was used for protein quantitation using the Protein 
Assay Reagent (Bradford assay) from Biorad. Lysates were then normalized in a fresh 
eppendorf tube and 5X SDS loading buffer was added before boiling samples for 5 
mins at 95 oC.  
SDS-PAGE and detection 
SDS-PAGE gels were prepared using the Biorad protean minigel apparatus. 
Components of these gels can be found in Appendix D. 13.5% -15% gels were used 
for detecting proteins such as Id1 and p16INK4a. 8%-12% gels were used for BMPR1A, 
phospho-Smad1/5/8, TAB1, TAK1, and 7.5% gel for c-Abl. Gels were run at 80-
120V along with protein standards (kaleidoscope marker, Biorad). Transfer by electric 
current was carried out using PVDF (Millipore) membranes for 2 hrs at 300mA, or 
overnight at 100mA in 4oC. Thereafter, membranes were stained with Ponceau S to 
check for integrity of transfer and stain removed with rinsing with TBST buffer 
(Appendix A). Membranes were then blocked with 5% (w/v) nonfat milk or 5% (w/v) 
BSA (for goat host, or all bmpr1A, 1B antibodies) for 1 hr before incubation with 
primary antibody overnight. The next day, primary antibody was removed, 
membranes washed 3X (5 mins per wash) with TBST, before adding secondary-HRP 
linked antibody for 1 hr. Membranes were then washed 4X and subjected to ECL 
solution for detection of protein bands. Varying film exposures were obtained before 
analysis of results. Membranes could then be stripped and reprobed if necessary. 
0.2M glycine solution was used for stripping PVDF membranes, for 15-10 mins and 








Cells were harvested on ice by washing twice with cold PBS, lysed using CO-IP 
buffer (Appendix A). Lysates were then left to rock at 4oC for 30 mins. The tubes 
were then centrifuged at max speed 16100g (or 14300rpm) for 10 mins (Note: all 
steps and centrifugation was performed at 4oC, with tubes kept on ice). A small 
aliquot (1-2ul) of supernatant was taken to perform protein quantitation using the 
Bradford assay with a spectrometer. All OD readings were ensured that they fall 
within the linear range of 0.1-0.5. Thereafter, OD measurements were calculated and 
lysates normalized with lysis buffer in a new tube. 25ul of anti-HA affinity beads 
(Roche) was added to each tube and left to rock for 2-3 hrs. After 
immunoprecipitation, the beads were spun down at 6000rpm for 8 mins and 
supernatant aspirated. Beads were subsequently washed 5 times, the first 3 times 
using CO-IP buffer, and the last 2 washes using cold PBS. Finally, after washing and 
final aspiration the beads were incubated with 2X SDS-PAGE loading buffer, boiled 
for 5 mins at 95 oC and ready to proceed with western blotting. 
 
 
2.11. RNA extraction  
 
Extraction and phase separation  
Prior to extraction, monolayer cells grown on culture dish were washed twice with 
cold PBS to remove residual media. Likewise, suspension cells (e.g. K562 and 
marrow cells) were centrifuged and cell pellet washed twice with PBS. TRIzol 
reagent (Invitrogen) was added (at 1ml per 10 cm2 of cells), to scrape and the lysate 
carefully dispersed by going through a 1ml sterile pipette tip 6 times before being 
placed in an eppendorf tube and left to sit at room temperature (rt) for 5-10 mins to 
permit complete dissociation of nucleoprotein complexes. Choloform (CHCl3) (at 
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0.5ml for every 1ml of TRIzol) was then added and tube vigorously hand-shaked for 
15 sec and left to sit at rt for another 2-3 mins. Thereafter the sample was centrifuged 
at 4oC, 12,000g for 15 mins. RNA will be exclusively contained within the colorless 
upper aqueous phase.  
Precipitation phase  
The aqueous phase was carefully transferred to a new tube. Precipitation starts with 
the addition of isopropanol (at 0.7ml isopropanol for every 1ml TRIzol used), mixed 
by hand and incubated at 10 mins rt before centrifugation at 4oC, 12,000g for 15 mins. 
A gel-like pellet was then formed at the bottom corner of tube. 
RNA recovery 
The supernatant was carefully removed, and pellet washed once with 1ml of 75% 
ethanol, and centrifuged at 12,000g for 10 mins. The RNA pellet was then air-dried at 
rt till its whitish pellet color turns translucent (approx 15 mins onwards). Pellet was 
then dissolved using RNase-free water, pipetted gently, and placed in 55oC waterbath 
for 20 mins. RNA was then measured at A260 for concentration, and at A260/280 ratio for 
purity check.  
 
 
2.12. RNA extraction of femur/long bones  
 
c-Abl adult mice were sacrificed and femur bones carefully removed from skin and 
muscle tissue using sterile dissection apparatus. The bones were rinsed with sterile 
cold PBS several times and placed in eppendorf tube, then immediately frozen using 
liquid nitrogen. Tubes containing long bones were then stored at -80oC. Prior to RNA 
extraction, the femurs stored at -80oC have to be broken down to powder form. A 
makeshift table was prepared, using dry ice and pre-chilled autoclaved mortar and 
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pestle. Femurs were grinded to powder with liquid nitrogen and further kept in dry ice 
until ready for RNA extraction using Trizol method as in 2.11. 
 
 
2.13. Reverse Transcription – Polymerase chain reaction (RT-PCR) 
 
Reverse transcription  
To assess the mRNA levels of Id1, Semi-quantitative RT-PCR assays were carried 
out.  Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen), 
quantitated, and then used as template for reverse transcription.  Reverse transcriptase 
AMV, RNase inhibitor, dNTPs and oligodT primers (Roche) were added and 
incubated at 42oC for 1 hr and thereafter heat inactivated at 90 oC for 5 mins. 
PCR 
The synthesized cDNA serves as a template to probe Id1 transcript, using DNA Taq 
polymerase (Roche). Beta-actin was used as an internal control. The various primers 
used, annealing temperature and cycle number for PCR are as listed below.   
 
Table 2.2 RT-PCR primers list 
 






Id1 F- ACTCACGCCTCAAGGAGCTGG      R- TCAGTGCGCCGCCTCAGCGACAC 57 30 
p16 F- AGTCCGCTGCAGACAGACTG   R- CGGGAGAAGGTAGTGGGTC   55 35 
Id3 F- GGTGCGCGGCTGCTACGAG   R- CAGGCCACCCAAGTTCAGTCC   56 27 




R- GCGGCCGAGCAGCAGCTGCGG   
58 25 
Smad7 F- TCCTGCTGTGCAAAGTGTTC R- AGTAAGGAGGAGGGGGAGAC 58 25 
BMPRIA F- TCGTCGTTGTATTACAGGAC   R- TTACATCCTGGGATTCAACC   56 35 
BMPRIB F- GCTTTGGACTCATCCTCTGG   R- CACTGGGCAGTAGGCTAACG   56 35 
BMPRII F-  GGTAGATAGGAGGGAACGGC   R- CACTGCCATTGTTGTTGACC   56 35 
Actin F- AGATGTGGATCAGCAAGCAG R- GCGCAAGTTAGGTTTTGTCA 56 25 
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2.14. Luciferase reporter assay 
 
C2C12 cells were counted and seeded (0.5x105 per 12-well) to achieve 45% 
confluency the next morning. Cells were transfected with DNA (total of 1.2ug DNA 
in equal proportions, along with 5ng TK-null plasmid as internal control) using 
Lipofectamine and Plus reagents (Invitrogen) for 3.5 hrs, and recovered with fresh 
complete media. Cells were harvested at an average of 48-72 hrs post-transfection 
(including starvation and/or BMP2 addition if needed). Harvesting starts from 
washing cells twice with PBS, adding 150ul 1X Passive Lysis Buffer (Promega) to 
rock for 20 mins, lysate collected, and spun down at 2000 rpm for 2 mins before 
reading. 20ul of lysate was used to determine luciferase and renilla activity using the 
luciferase and STOP and Glo reagents (Promega) respectively, in the TD20e 
luminometer under the dual-luciferase mode. Ratio of luciferase/renilla activity was 
obtained and the normalized values plotted on a chart for analysis. 
 
 
2.15. RNA Interference 
 
siRNA preparation and transfection 
Murine MAP3K-TAK1 siRNA (ON-Targetplus SMARTpool L-040718-00-0010) and 
non-target pool siRNA as control were resuspended in 1X siRNA buffer to a stock 
concentration of 20nM and stored in aliquots at -20oC (Dharmacon). C2C12 cells 
were seeded the night before at a density of 1.2-1.5x105 per 6-well in antibiotic-free 
complete media to achieve 70% confluence the next day. siRNA and non-target 
control were then diluted to 2uM final concentration and transfected using 
Dharmafect 3 reagent according to manufacturer’s instructions and left to incubate for 
48 and 60 hrs. Cells were then treated with BMP2 for various time points and 
harvested for western blot analysis.  
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The siRNA product - Mouse MAP3K7, NM_172688 (10nmol) consist of 4 pooled 
duplex primer pairs and target sequences are available online at 
http://www.dharmacon.com/predesignedsirna/search.aspx. 
 
2.16. Cloning  
 
BMPRIA deletion mutants were PCR-cloned with reverse primers flanking the 30, 35, 
45 and 50 kDa regions of full length wild type BMPR1A expression construct (gift 
from Dr Chen Ye-Guang).  PCR products were then gel-purified and digested with 
XbaI and EcoRI, and ligated into pCDNA-NE vector (N’-terminal HA-tag) using 
Rapid Ligation Kit (Roche). Transformation into competent E. coli (DH5α) was then 
carried out at 42oC, left to recover at 37 oC in 0.5ml LB broth (without selection drug) 
for 1 hr and plated onto ampicillin LB agar plates overnight at 37oC. Single 
ampicillin-resistant colonies were isolated next day and grown with 4ml LB broth 
(with ampicillin) overnight. Purification of plasmid was performed with Miniprep Kit 
(Qiagen) and positive clones confirmed with enzyme digestion (for size) and 
sequenced using dideoxy termination method. 
 
 
2.17. Site directed mutagenesis 
 
Using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene), point 
mutations were created on BMPRIA. PCR was carried out at annealing temperature of 
60oC for 18 cycles, followed by extension at 68oC for 12 mins.  DpnI was used to 
remove orginal BMPRIA template DNA (methylated, hence recognized and 
digested). BMPRIA single tyrosine mutants A to E were cloned from full length 
BMPRIA as template, while combination mutants F to I were cloned from A-E as 
templates, at HindIII and NheI sites into pCDNA-NE vector. Mutant plasmids were 
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then transformed to isolate positive clones and mutations confirmed by sequencing 
along with BLAST (NCBI) search online. 
 
 
2.18.  Densitometric analysis 
 
To measure the band intensity of blots and set it against control protein/RNA bands 
for normalization, the Bio-Rad GS-700 imaging densitometer was used. Using the 
Quantity one program, the bands on X-ray films were boxed and their total intensity 
volume quantitated against film background. Corrected integrated volumes were 
taken, and ratio calculated against respective control bands. The arbitrary units were 
then used for graphical representation.    
 
   
2.19.  Statistical analysis and data presentation  
 
All experiments were performed at least 3 times. Statistical analysis was performed 
























CHAPTER 3  
 
PREMATURE SENESCENCE OF C-ABL-/- OSTEOBLASTS AND THE UP-
REGULATION OF p16INK4a, A BIOMARKER OF AGING  
 
 
3.1 c-Abl-/- osteoblasts have decreased proliferation ability and undergoes 
premature senescence 
 
c-Abl-/- mice show features of senile osteoporosis, this phenotype primarily caused by 
a decline in the function of osteoblasts (Li et al., 2000). In addition to the 
differentiation defects, it was found that c-Abl-/- osteoblast cultures were particularly 
difficult to maintain with increasing passages, and generally senesce after the 4th to 5th 
passages. This was in contrast to the wild type osteoblasts, which could be maintained 
past another 3 to 4 more passages. To study the growth potential of these osteoblasts, 
a modified 3T3 procedure was used (Randle et al., 2001). Osteoblasts were derived 
from single cavarial bone of an 18-19 day fetus and plated onto a 6-well or 35 mm 
dish (counted as passage 1). Upon confluence, these cells were further expanded to a 
60 mm dish (passage 2) and then to a 100 mm dish (passage 3) before being used for 
experiments. Cells were counted at every passage (post 3 days) and further re-plated 
at 4 x 105 cells/60 mm dish till the cells stop dividing. We detect little difference in 
growth rates of c-Abl mutant and wild type osteoblasts of early passages (Fig. 3.1A). 
However, after the 3rd passage the growth rates differed tremendously, since c-Abl 
mutant osteoblasts ceased growing at passage 5, while wild type osteoblasts could be 
maintained till the 8th passage before senescing eventually. The percentage of dead 
cells was factored in all cell counts and was found to be in similar proportions, 
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therefore indicating that c-Abl-/- osteoblasts contained an innate defect in proliferating 
capacity. 
 
Moreover, staining of senescence associated--Galactosidase (SA--Gal), a 
histochemical marker active only in senescent cells (Dimri et al., 1995), revealed an 
increase in percentage of SA--Gal positive cells in c-Abl-/- osteoblasts with 
continuous passage (Fig. 3.1B). As alterations in cell metabolism and morphology 
follow replicative senescence (Ben-Porath and Weinberg, 2004), the increase in SA--
Gal staining with both mutant and wild type osteoblasts over time reveals that primary 
osteoblasts undergo senescence, albeit with the mutant osteoblasts at an accelerated 
rate.  
 
This premature senescence phenotype of c-Abl-/- osteoblasts was further supported by 
the findings that c-Abl-/- mice possessed lower osteoblast numbers in their bones (Fig. 
3.1C). In vivo BrdU labeling on E19 embryonic bones validated the lower growth 
rates as c-Abl-/- bones had fewer BrdU positive cells in the S phase of cell cycle, as 
compared to its wild type counterpart (Fig. 3.1D). Hence, osteoblasts lacking c-Abl 































Fig. 3.1. c-Abl-/- osteoblasts do not grow well and senesces prematurely.  
(A) Growth of c-Abl-/- and wild type osteoblasts. Calvarial osteoblasts were cultured 
as described and cell count numbers plotted against passage numbers. (B) 
Histochemical staining of SA--Gal. Mutant and control osteoblasts were cultured as 
in (A), then fixed and stained at a neutral pH for -Gal. Percentage of SA--Gal 
positive cells at each passage was shown. (C) c-Abl-/- bone sections showed reduced 
number of osteoblasts. *, p<0.05. Femur bones of 2-month old c-Abl-/- and wild type 



















































Fig. 3.1. c-Abl-/- osteoblasts do not grow well and senesces prematurely. 
(continued) 
(D) Reduced osteoblast proliferation in c-Abl-/- mice. BrdU was injected into pregnant 
mice at E19 for 2-3hours and the mice sacrificed. The embryos were fixed and cryo-
embedded and stained for BrdU positive cells in the long bones.  (Black arrows 


















3.2 p16INK4a is up-regulated in c-Abl-/- osteoblasts 
 
 
The two signaling pathways known to mediate senescence are the p16INK4a/pRB and 
the p19ARF/p53 pathways (Lundberg et al., 2000). In order to distinguish the pathway 
that governs c-Abl mediated senescence, the expression of key proteins of these 
pathways were monitored. Osteoblasts were harvested at passage 4 and 6, when 
mutant cells ceased to divide. Passage 4 cavarial osteoblasts correlate with the time 
frame whereby considerable difference in total viable cell numbers could be seen 
between c-Abl-/- and wild type osteoblasts (Fig. 3.1A).  It was observed that the 
protein expression of p19ARF and p21 remain unchanged at either passage points in 
both c-Abl-/- and normal osteoblasts, suggesting the lack of significant p19ARF or p21 
involvement in mediating c-Abl-/- senescent phenotype (Fig. 3.2A). On the other hand, 
changes in p16INK4a expression was visibly noted, first an up-regulation with 
increasing passage (as cells senesce), and next, the apparent difference in mutant 
versus wild type osteoblasts (Fig. 3.2A). It was noticed that with all western blot 
analyses, the levels of p16INK4a expression in wild type osteoblasts never achieved the 
maximal levels seen in c-Abl-/- at parallel passages, suggesting that up-regulation of 
p16INK4a may participate in the initiation and/or maintenance of senescence in 
osteoblasts.  
 
More importantly, ectopic expression of p16INK4a, to a level comparable to that of c-
Abl-/- osteoblasts, resulted in a senescent-like phenotype in early passage primary wild 
type osteoblasts; flattened cell morphology and two-fold reduction of BrdU 
incorporation (Fig. 3.2B and Fig. 3.2C). To support the findings that p16INK4a up 
regulation contributes to osteoblast senescence, immunohistochemical staining of 
p16INK4a protein in the long bones of c-Abl adult mice was carried out. It revealed 
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higher levels of p16INK4a in c-Abl mutant mice, mostly concentrated at the growth 
plate region of the long bone, where active osteoblasts reside (Fig. 3.2D). p16INK4a 
expression was also examined in the long bones of E18.5 embryos and they show a 
similar staining pattern between mutant and wild type, though to a lesser extent 
(results not shown). Extraction of RNA from the adult femurs also revealed higher 








I have examined if the loss of p16INK4a in c-Abl-/- osteoblasts could revert the 
senescent phenotype. p16INK4a expression was knocked down in c-Abl-/- osteoblasts 
using p16shRNA (courtesy of Dr. S.Lowe) and its proliferation ability assessed by 
counting and replating every 4-5 days. It was observed that the viability of 
p16shRNA-c-Abl-/- osteoblasts could overcome the negative or neutral growth rate (at 
least 2 fold in twice repeated experiments) briefly over the 3rd-4th passage onwards, 
and ceased to divide thereafter (results not shown). This slight ability to overcome its 
usual senescing phenotype may indicate once p16INK4a –mediated senescence pathway 
is induced in osteoblasts, they become irreversibly resistant to p16INK4a silencing by 
p16INK4a shRNA, or that for this rescue phenotype to fully manifest it may require 
additional factors other than p16INK4a per se. Nevertheless, the role of p16INK4a in 
osteoblast survival in vivo was examined using TUNEL assay on c-Abl embryonic 
bone sections (Fig 3.3) and it revealed that c-Abl-/- bones contain more cells 
undergoing apoptosis at the growth plate region and further north, compared to wild 





















Fig. 3.2.  Up-regulation of p16INK4a expression in c-Abl-/- cells.  
(A) c-Abl-/- osteoblasts expressed elevated levels of p16INK4a, but not p19ARF or p21 
during replicative senescence. Mutant and control osteoblasts were cultured as in Fig. 
3.1, and at day 3 of indicated passage, cells were harvested and protein lysates 
normalized before western blot analysis. (B) Ectopic expression of p16INK4a led to 
senescence-like phenotypes. Wild type osteoblasts were infected with control empty 
retroviruses or viruses harboring p16INK4a. Cells were selected against puromycin and 
cultured. Bottom panel: Western blot to show levels of infected p16INK4a, compared to 
control empty virus. (C) Forced expression of p16INK4a resulted in growth reduction, 
justified by a 2-fold reduction in S phase cells. The infected wild type osteoblasts 
were seeded in 96-well plates at various cell densities in triplicates and BrdU labeling 
was carried out overnight. Measurement of BrdU incorporation was determined by 
ELISA and averaged absolute units obtained. This experiment was repeated twice on 






























































Fig. 3.2. Up-regulation of  p16INK4a expression in c-Abl-/- cells (continued).  
(D) In vivo analysis of mouse bone sections. c-Abl adult mice femurs were 
decalcified and embedded in methyl methacrylate (MMA), sectioned and stained for 
p16INK4a protein (40X magnification). (Top - c-Abl+/+, Bottom - c-Abl-/-). (E) mRNA 
levels of p16INK4a examined in long bones of an c-Abl adult mice pair. Total RNA was 


















Fig. 3.3. Increased apoptosis in c-Abl-/- osteoblast long bones. 
TUNEL assay immunostaining was performed on the long bones of c-Abl E18.5 day 


















3.4 Summary  
 
 
Here, the osteoporotic phenotype of c-Abl-/- mice were further studied in detail at the 
cellular level. Primary cells were isolated from the cavarial bone to obtain relatively 
pure populations of osteoblasts for culture and biochemical assays. The osteoblasts 
used in this project were essentially unipotent osteoprogenitors, (or preosteoblasts, 
referred to as osteoblasts in this report) as they have the capacity to proliferate but do 
not express alkaline phosphatase or osteocalcein, markers for differentiated 
osteoblasts. However, in the presence of BMP2, or ascorbic acid and -glycerol 
phosphate, they could differentiate into mature osteocytes. 
 
Proliferation assay demonstrates a slower growth rate on c-Abl-/- osteoblasts (Fig 
3.1A), and more advanced stage of senescence using the -galactosidase marker (Fig 
3.1B) with progressive passages when compared to wild type cells. These results 
complemented the in vivo data that c-Abl-/- mice show lower osteoblast numbers (Fig 
3.1C), as well as significantly fewer cells in S phase in the long bones of c-Abl-/- 
embryos. Hence, the senile osteoporotic phenotype in c-Abl-/- mice stems from an 
innate problem with a reduced proliferation potential of its osteoblasts, apart from the 
defect in osteoblast function.   
 
p16INK4a was observed to be dramatically up-regulated in c-Abl deficient osteoblasts 
(Fig 3.2A). To confirm if p16INK4a could mediate the senescence of osteoblasts, gain 
of function study on wild type osteoblasts revealed a senescent outcome, with cells 
displaying half the amount of cells in S phase, when compared to its control (Fig 3.2B 
and C). Hence, the stable p16INK4a expression in c-Abl-/- osteoblasts could cause 
senescence, as without c-Abl, osteoblasts exhibit an advanced stage of senescence. 
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This outcome was exemplified by femur sections of adult mice, in which c-Abl 
mutant display increased staining for p16INK4a, especially in the growth plate region, 
while RNA extracted from the long bones of adult mice pair expressed higher levels 
of p16INK4a transcript (Fig 3.2D and E).  
 
Moreover, it has been shown that p16INK4a may be involved in regulating cell survival, 
in addition to senescence. Tunel assay performed on c-Abl E18.5 embryos showed 
increased apoptotic cells in c-Abl mutant long bones, suggesting that in the absence of 
c-Abl, higher p16INK4a expression correlates with increased senescence and apoptosis 
(Fig 3.3). Therefore c-Abl exerts a positive role in cell survival in osteoblasts, though 
it is not clear if the upstream regulators of p16INK4a may activate apoptotic/survival 





























UP-REGULATION OF p16INK4a IN C-ABL-/- OSTEOBLASTS IS 
ACCOMPANIED BY INCREASED ERK1/2 ACTIVATION AND 
DECREASED ID1 EXPRESSION 
 
Chapter 3 describes p16INK4a as the candidate mediator of premature senescence in c-
Abl-/- osteoblasts. The mechanisms behind regulation of p16INK4a in cellular 
senescence remains complicated with its heterogenous expression in different cell 
types or context. To date, some key transcription factors have been reported to 
regulate of p16INK4a expression. In p16INK4a-pRB mediated senescence, Id1, E proteins 
and Ets proteins- Ets1 and Ets2 can modulate p16INK4a transcription.  
 
Id1 delays senescence and was specifically involved in pRb, and not p19ARF/p53-
mediated senescence (Tang et al., 2002, Alani et al., 2001). Id1 was a negative 
regulator of p16INK4a by binding and sequestering the Ets1, which binds and activates 
the p16INK4a promoter. The reciprocal relationship of Id1 repression and Ets1 up-
regulation was stable, and correlated with promoting p16INK4a expression (Ohtani et 
al. 2001). Similarly, the E protein–E47, a member of the HLH family, was also found 
to be antagonized by Id1 to block p16INK4a transcription (Zheng et al., 2004) 
 
On the other hand, the MAPK cascade (Ras-Raf-MEK-ERK) was required for the up-
regulation of p16INK4a and p19ARF. Transcription factor Ets2, was found to be a 
downstream target of the MAPKs (Lin et al., 1998). Hence the primary activators of 
p16INK4a expression are the MAPKs, which activate Ets1/2, while Id1 serves to oppose 
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4.1 Role of MAPK pathway in the up-regulation of p16INK4a 
 
p16INK4a can be positively regulated by the Ras-Raf-MAPK pathway, and consistent 
with this notion it was found that along with elevated p16INK4a expression, c-Abl-/- 
osteoblasts also exhibited higher levels of activated ERKs (phospho-p42/p44) (Fig. 
4.1A). The overnight osteoblast cultures displayed intensified levels of activated 
ERK1/2, compared to cells cultured for 3 days (refer to passage “-“ and “4”), 
probably due to the presence of fresh growth factors in the serum. Yet activated 
ERK1/2 remained higher in c-Abl mutant osteoblasts than in wild type cells, at all 
passage points (Fig. 4.1A). This reflected the p16INK4a expression profile between the 
both cell types.  
 
Furthermore, specific inhibition of ERK using MEK inhibitor U0126 also reduced 
p16INK4a levels in both osteoblast types, validating that ERK activation have a positive 
impact on p16INK4a expression (Fig. 4.1B). The fact that ERK inhibition in c-Abl 
mutant did not reduce the levels of p16INK4a expression to that of wild type osteoblasts 
suggests that p16INK4a up-regulation may involve other factors apart from ERK1/2, 
and possibly the inhibition of MEK (U0126) may have displayed slight redundancy 
by affecting the regulation of other proteins necessary for p16INK4a regulation in the 
absence of ERK. Nonetheless, deficiency of c-Abl could alter ERK activation and this 
was affirmed by enhanced ERK activation upon inhibition of c-Abl using imatinib 








Fig. 4.1. Enhanced activation of ERK1/2 in c-Abl-/- osteoblasts.  
(A) Mutant and wild type cells were cultured as in Fig. 3.1 and cells collected at day 3 
of each passage. Passage “n/o” stands for cells that were grown overnight. Harvested 
lysates were subjected to western blot analysis. (B) Inhibition of ERK1/2 activation 
repressed p16INK4a expression. Early passage (P2) osteoblasts were treated with 2 
different doses of U0126 for 3 days and harvested for western blot (lanes 1 and 4 as 
non-treatment control). (C) c-Abl inhibition enhances ERK activation. Wild type 
osteoblasts (ctrl) were serum starved overnight and then treated with 1uM of 
STI571/imatinib for 2 hours. (D) Reconstitution of c-Abl in c-Abl-/- osteoblasts 
restores the normal activation of ERKs. Bottom panel: protein levels of retroviral 
expressed c-Abl in wild type and mutant osteoblasts.  
+/+ 
[STI571] 
Ctrl    +[STI571] 
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ERK activation (Fig. 4.1D). Taken together, these results summarize c-Abl negative 
effect on ERK activation and will be further discussed in Chapter 7. 
 
 
4.2 An opposing role of Id1 in p16INK4a up-regulation 
 
 
The expression of p16INK4a is largely controlled by the helix-loop-helix family of 
transcription factors, namely the Ets1/2 as positive regulators and Id1 as a negative 
regulator (Ohtani et al., 2001). Besides, Id1 involvement in p16INK4a-dependent 
senescence have been well studied (reviewed in Zebeedee and Hara, 2001, Ruzinova 
and Benezra, 2003), which raised the rationale to probe the expression of these 
proteins in c-Abl-/- osteoblasts. While the expression of Ets1 and Ets2 remained 
unchanged (data not shown), the levels of Id1 protein was down-regulated in c-Abl-/- 
osteoblasts (Fig. 4.2). Since Id1 levels did not change with increasing passages, it was 
possible that the constant p16INK4a up-regulation during osteoblast senescence could 
be triggered by other factors other than Id1. Nevertheless, an inverse relationship 
could be observed in untreated osteoblasts; when p16INK4a expression was increased, 
Id1 level dropped (Fig. 4.1B, lanes 1 and 4). This expression pattern was also 
observed in long bone sections of c-Abl fetuses (E18.5), where Id1 immunostaining is 









































Fig. 4.2. Down-regulation of Id1 in c-Abl-/- osteoblasts. 
The osteoblasts were harvested at day 3 following the designated passage number and 





















The increase in p16INK4a expression in senescent osteoblasts correlates with aging-
associated phenotypes such as increased -Gal staining and a reduction in BrdU 
positive cells. What are the upstream mediators that regulate p16INK4a expression in c-
Abl-/- osteoblasts? The endogenous levels of activated MAPK-ERK1/2 was found to 
be dramatically elevated in c-Abl-/- osteoblasts, when compared to wild type cells, and 
this increase remained consistently unchanged, regardless of osteoblast passage 
number (Fig. 4.1A). In addition, the presence of c-Abl displays an inhibitory mode on 
ERK activation, as blocking c-Abl kinase activity using imatinib/STI571 relieved the 
ERK inhibition in wild type osteoblasts (Fig. 4.1C), while ERK repression was 
restored in c-Abl-/- osteoblasts, when c-Abl was reinstated (Fig. 4.1D).  
 
On the other hand, as Id1 has been shown to inhibit p16INK4a expression in the 
p16INK4a-RB mediated senescent pathway. Aligned to our results, Id1 expression was 
diminished in c-Abl-/- osteoblasts and at the in vivo level, in the long bones of c-Abl-/- 
embryos (Fig 4.2 and results not shown). As a result the lack of sufficient Id1 levels in 
c-Abl mutants is likely to be one of the reasons why p16INK4a was higher in the 
mutants than in wild type osteoblasts. 
 
Hence, the positive impact of increased ERK activation and the negative influence of 
Id1 exemplify the actions of two opposing mediators that must be balanced in order to 
achieve a desired output of p16INK4a on osteoblasts. Yet, p16INK4a expression in c-Abl 
osteoblasts suggests the existence of regulation by separate pathways; one that 
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involve an ERK1/2 mediated pathway independent of Id1, and another pathway that 



















































C-ABL POSITIVELY REGULATES ID1, VIA THE BMP-SMADS-1/5/8 
SIGNALING PATHWAY 
 
Previous chapters have demonstrated the strong correlation of Id1 up-regulation with 
p16INK4a down-regulation in the premature senescence of osteoblasts (depicted in 
chapter 3). This chapter further investigates the upstream regulation of Id1 and its 
relationship with the BMP pathway, to understand how Id1 expression is affected by 
c-Abl deficiency during osteoblast senescence. 
 
 
5.1 c-Abl is likely to augment Id1 expression via the BMP pathway 
 
 
Having shown that c-Abl-/- osteoblasts expressed reduced levels of Id1, and Id1 is a 
direct target gene of the BMP pathway (Miyazono and Miyazawa, 2002), it was 
imperative to understand how c-Abl regulates Id1 expression. More so as it is known 
that BMPs are expressed and secreted by osteoblasts, and BMP signaling is essential 
for regulating osteoblast differentiation and bone remodeling (Chen et al., 2004). To 
demonstrate that c-Abl is involved in BMP2-induced Id1 expression, c-Abl-/- and 
control osteoblasts were serum starved overnight and stimulated with increasing doses 
of BMP2 (Fig. 5.1A). Both cells were highly sensitive to BMP2, with dramatic Id1 
induction even at a low dose of 10ng/ml BMP2, while the Id1 levels in mutants 
remained sub-optimal, and did not reach that of wild type osteoblasts. Surprisingly, 
BMP2 at the dose of 200ng/ml failed to induce Id1, probably due to feedback 
regulation in the cell response to high concentrations of BMP2. In addition, inhibition 
of c-Abl using imatinib was able to repress BMP2-induced Id1 expression in wild 
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type osteoblasts (Fig. 5.1B), indicating c-Abl was required for maximal induction of 
Id1.  
 
To test if c-Abl reconstitution could ultimately rescue the defect of BMP-induced Id1 
expression in c-Abl-/- osteoblasts; retroviruses carrying the c-Abl gene and empty 
vector as control were infected into these cells and then challenged with 10ng/ml of 
BMP2. The time course study showed that c-Abl could indeed rescue the otherwise 
weak Id1 induction in c-Abl-/- osteoblasts, when compared to the vector control in the 
same set of cells, even with a low dose of BMP2 (Fig 5.1C). This implies c-Abl plays 




5.2 c-Abl  up-regulates Id1 transcription 
 
 
To explore the extent of c-Abl regulation of the Id1 gene, transcription-based assays 
were carried out. In RT-PCR assays, overexpression of c-Abl or the constitutively 
activated v-Abl DNA enhanced the endogenous Id1 mRNA expression, with stronger 
induction being seen with v-Abl in osteoblast-like cell line MC3T3 (Fig. 5.2A).  
 
It was shown that c-Abl can potentiate BMP-induced Id1 at the protein and 
transcription levels (Fig 5.1C, 5.2A). Luciferase reporter assays using Id1 promoter 
construct were transfected into myoblastic cell line C2C12. Constructs expressing 
effectors of BMPs; Smad1 and Smad4 with BMP2, or BMP2 alone was able to 
enhance Id1 transcription, yet c-Abl itself could only induce a 2-fold increase in basal 
Id1 transcription. The kinase activity of Abl was important for this, as constitutive 











Fig. 5.1. c-Abl is required for optimal induction of Id1.  
(A) Reduced Id1 induction by BMP2 in c-Abl-/- osteoblasts. c-Abl mutant and wild 
type osteoblasts were serum-starved overnight and stimulated with various doses of 
BMP2 for 4 hrs and the levels of Id1 determined by Western blot. (B) Imatinib 
treatment inhibits Id1 induction by BMP2. Primary osteoblasts were pre-treated with 
1uM imatinib for an hour prior to adding of low doses of BMP2 for 1 hr. (C) A time 
course study of Id1 induction in c-Abl-/- and c-Abl reconstituted c-Abl-/- osteoblasts 





kinase-dead c-Abl [KD] remained unchanged (Fig. 5.2B), this also signifies the 
effects of v-Abl and the BMP-Smad pathway is not mutually exclusive. Treatment of 
C2C12 cells transfected with Id1 promoter-luciferase gene with imatinib to inhibit 
endogenous c-Abl also repressed Id1 transcription, as well as BMP-induced Id1 
transcription (Fig. 5.2C), stressing the need for c-Abl kinase activity in Id1 up 
regulation, whether direct or indirect. 
 
Importantly, RT-PCR assay confirmed that c-Abl regulates Id1 at the transcript level 
as the reconstitution of c-Abl into c-Abl-/- osteoblasts could rescue the BMP-induced 








Since c-Abl positively regulates Id1 gene transcription, and more so with BMP-
induced Id1, It was necessary to determine if BMP-Smads 1/5/8 could be affected by 
c-Abl deficiency, since Smads1 and Smad4 are the upstream regulators of Id1 (Lopez-
Rovira et al., 2002), and/or if this involved a Smad-independent mechanism. c-Abl-/- 
osteoblasts were subjected to BMP2 in various doses, revealing compromised Smad 
1/5/8 activation, as well as basal levels when compared to wild type cells (Fig. 5.3A). 
Also, while the basal levels of activated Smad 1/5/8 was significantly reduced in 
mutant cells, they could be restored by the reconstitution of c-Abl (Fig. 5.3B). Both 
suggest the compromised Smad signaling could be responsible for the down 
regulation of Id1. This was not confined solely to osteoblasts, as c-Abl-/- MEFs also 


















Fig. 5.2. c-Abl regulates Id1 at the level of transcription. 
(A) c-Abl overexpression promoted BMP-induced Id1 expression. MC3T3 cells were 
transfected for 24 hrs, and further treated with 100ng/ml of BMP2 for 6 hrs. The 
amount of Id1 mRNA was determined by RT-PCR. (B) c-Abl acted directly on the 
Id1 promoter. Id1 promoter-luciferase reporter was co-transfected with Smad1 and 
Smad4, c-Abl, c-Abl kinase dead [KD], or v-Abl into C2C12 cells for 3.5 hrs. These 
cells were then treated with 100ng/ml BMP2 overnight for 16 hrs and the luciferase 














Fig. 5.2. c-Abl regulates Id1 at the level of transcription (continued). 
(C) Imatinib mesylate inhibited Id1 promoter activity. As before, Id1 promoter-
luciferase reporter was transfected into C2C12 cells. The cells were then pretreated 
with 1uM imatinib for 2 hrs prior to adding 100ng/ml BMP2 for 16 hrs. Luciferase 
activity was measured, and renilla used as an internal control. (D) RT-PCR assay 
showed that BMP2-induced Id1 mRNA was significantly reduced in c-Abl-/- 
osteoblasts and can be rescued upon c-Abl reconstitution using retrovirus. c-Abl 
mutant and control osteoblasts were stimulated with 5ng/ml BMP2 and harvested at 




As the activation of Smads 1/5/8 would result in changes to downstream events of 
BMP signaling since they mediate the transcription of various target genes, RT-PCR 
was carried out in the same conditions as in Fig 5.2A to study the mRNA levels of 
other target genes. BMP early target genes such as Id3 and Smad6 gave rise to similar 
profiles as Id1 transcript, whereby attenuated response to BMP2 exist with the lack of 
c-Abl, and this deficiency could be restored with c-Abl reconstitution (Fig 5.3D). 
These results reaffirms the hypothesis that c-Abl acted positively on the BMP 




5.4 BMP sustains Id1 expression to promote cell proliferation 
 
To place in context the logic behind Id1 up-regulation by c-Abl in the senesence of 
osteoblasts, the Id1 protein was overexpressed in c-Abl-/- osteoblasts using retrovirus 
(Fig. 5.4A). Levels of Id1 overexpressed in mutant cells matched that of wild type 
levels and was sufficient to down regulate p16INK4a, and extented the lifespan of 
mutant cells by three doublings (results not shown). This establishes the basis that c-
Abl elevation of Id1 served to down regulate p16INK4a, and delay the senescent fate of 
osteoblasts, and is consistent with findings that Id1 overexpression extended the 
lifespan of keratinocytes and ES cells (Rheinwald et al., 2002, Ying et al., 2003). 
 
In order to prove BMP signaling affects p16INK4a expression via Id1, BMP2 and 
BMP4 antagonists: noggin and chordin, were added to culture media of wild type 







Fig. 5.3. c-Abl regulates the activation of BMP-Smad1/5/8. 
(A) Reduced Smad1/5/8 activation in the presence of BMP2. c-Abl-/- and control 
osteoblasts were stimulated with various concentrations of BMP2 for 4 hrs and 
analyzed by western blot using anti-p-Smad1/5/8 antibodies. (B) The attenuated basal 
levels of activated Smads in c-Abl-/- osteoblasts were restored by c-Abl reconstitution. 
(C) Profile of Id1, Smad1/5/8, p16INK4a and ERKs expression in response to BMP2 in 
c-Abl MEFs is similar to that of osteoblasts. MEFs isolated from c-Abl-/- mice and 
control littermates were cultured to passage 3. Cells were treated with BMP2 for 














Fig. 5.3. c-Abl positively regulates BMP signaling via Smad1/5/8 activation. 
(D) RT-PCR assays conducted in the same manner as in Fig. 5.2D also revealed the 
loss of BMP2 induction on BMP target genes, and can be rescued to wild type levels 
with the addition of c-Abl back to c-Abl-/- osteoblasts. 5ng/ml BMP2 was added for 





















expression was concurrently elevated with increasing dosage of BMP antagonists 
(Fig. 5.4B). Moreover, BMP2 was able to down regulate p16INK4a in osteoblast 
cultures (Fig. 5.4C), also reflected in c-Abl MEFs (Fig. 5.3C), stressing the 
importance of an intact BMP pathway in influencing p16INK4a expression. 
Nonetheless, the delayed rate of p16INK4a up regulation (Fig. 5.4B), and resistance to 
absolute repression of p16INK4a (Fig. 5.4A and C) also meant that the regulation of 



































Fig. 5.4. BMP2-induced Id1 up-regulation promotes osteoblast proliferation. 
(A) Retroviral expression of Id1 down-regulated p16INK4a in c-Abl-/- osteoblasts. (B) 
Blocking BMP signaling with noggin and chordin in osteoblasts down-regulates Id1 
and up-regulates p16INK4a. Wild type osteoblasts were cultured in the presence of 
increasing doses of noggin and chordin for 3 days and the levels of p16INK4a, Id1 and 
phospho-Smad1/5/8 determined by western blot. (C) BMP2 was able to down-
regulate p16INK4a expression in osteoblast cultures. Normal osteoblasts were seeded at 
1x105 cells/60mm dish, and treated with BMP2 for 2 or 4 days. The basal levels of 
p16INK4a were determined by western blot. Graphical representation of normalized 







































In c-Abl wild type osteoblasts, the homeostatic levels of p16INK4a is maintained by Id1 
and counter-balanced by ERKs to achieve a normal replicative senescence program 
reflective of primary cells.  The reduction of Id1 expression in c-Abl mutant cells 
prompted further investigation of its role not only in affecting p16INK4a mediated 
senescence, but also in the search for a connection between c-Abl and Id1. c-Abl was 
found to positively regulate Id1 expression, as seen when comparing the basal Id1 
protein expression levels, as well as under BMP2 induction , where the difference was 
clearly observed under conditions of serum starvation (Fig 5.1A). In addition, 
inhibition of c-Abl on a separate batch of wild type osteoblasts shows that Id1 
expression is augmented by c-Abl under low doses of BMP2. However, as serum-free 
media was used for imatinib pretreatment period, as well as on non-treated 
osteoblasts, and the density of protein cell lysate collected was lesser in comparison to 
other sets, this could account for the minimal Id1 expression seen in lane1 of control 
set cells (Fig 5.1B). Conversely, the rescue of BMP2-induced Id1 in c-Abl knockout 
osteoblasts is restored with reconstitution of c-Abl (Fig 5.1C). Therefore this 
suggested that c-Abl could be involved in BMP signaling and affect its target gene 
Id1. Furthermore, transient overexpression of v-Abl could significantly boost basal 
Id1 mRNA, while the addition of BMP2 saturates this effect by the maximal induction 
of Id1 in MC3T3-E1 cells. This occurred to a lesser extent in the c-Abl overexpressed 
set, probably due to the difficulty of getting sufficient c-Abl kinase activation to occur 
in these cells (Fig 5.2A). c-Abl also appears to create an additive effect on Id1 
transcription, and the degree of Id1 induction depended on its kinase action as the 
kinase dead c-Abl, as well as inhibition of Abl kinase by imatinib, repressed Id1 
transcription, demonstrated by the Id1-promoter reporter assays (Fig 5.2B and C). 
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Again, the rescue of endogenous Id1 and BMP-induced Id1 mRNA in c-Abl-/- 
osteoblasts by c-Abl reconstitution (Fig 5.2D) was consistent with the pattern seen at 
the protein level (Fig 5.1C). The rapid induction of BMP2-induced Id1 by c-Abl led to 
the analysis of BMP-Smads expression, and indeed the activation of Smads1/5/8 was 
compromised by the loss of c-Abl, particularly at the endogenous stage. This 
phenomenon was not restricted to osteoblasts as c-Abl-/- MEFs also displayed poorer 
BMP2-induced Id1 expression and Smad activation. Smads are transcription factors 
that regulate a large repertoire of genes, hence this led to extending the analysis of c-
Abl reconstitution studies to more BMP target genes. Undoubtedly, the transcription 
of various immediate-early direct target genes of the BMP pathway were found to be 
affected (Fig 5.3). This led to the conclusion that c-Abl could participate in the BMP 
signaling pathway, and do so in a positive manner. 
 
To confirm if c-Abl’s involvement in BMP pathway could modulate p16INK4a 
mediated senescence in osteoblasts, Id1 overexpression in c-Abl-/- osteoblasts could 
down-regulate p16INK4a expression and overcome the premature senescence to some 
extent (Fig 5.4A). In addition, BMP2 could repress p16INK4a expression further in 
proliferating osteoblasts with increasing dosage (Fig 5.4C), while blocking BMP 
signaling and feedback by BMP antagonists created an outcome that supported rising 
evidence for BMP regulation of p16INK4a, as it appears the repressive effect of BMP 
on p16INK4a was lifted, in a dose dependent manner, and correlated with repression of 
Id1 and Smad activation. Thus, c-Abl could augment BMP2-induced Id1 to promote 





CHAPTER 6  
 
 
C-ABL ACTS UPSTREAM OF SMADS-1/5/8 AT THE BMP RECEPTOR 
LEVEL TO AUGMENT BMP-SMAD SIGNALING   
 
 
The structural features of BMP receptors were described in chapter 1.4.1 (page 37). 
Smads1/5/8 can only be activated by type I BMPRs (BMPRIA), therefore BMPRIA 
determines the specificity of Smad signaling. Proper BMP-Smad signaling requires 
intact type I BMP receptors, as studies manipulating BMPRIA have shown. Truncated 
forms of BMPRIA caused cells to differentiate into myotubes (Namiki et al., 1997), 
and induced dorsal mesoderm formation instead of ventralization in Xenopus embryos 
(Suzuki et al, 1994). So, mutated BMPRIA appears to exert a dominant negative 
effect in vitro and in vivo, since the phenotype completely reversed. 
 
In this chapter the roles of BMP receptors are covered, to gain an understading into 




6.1 c-Abl phosphorylates BMP type I receptors 
 
 
The endogenous transcript and protein levels of BMP receptors 1A, 1B and II were 
examined in c-Abl wild type and knockout osteoblasts and MEFs. No obvious 
changes were observed, which ruled out varying innate expression levels as the reason 
behind decreased Smad activation in c-Abl-/- osteoblasts. (Fig. 6.1A; transcript in 
osteoblasts, protein in MEFs). To determine the likelihood of post-translational 
modification of the receptors, c-Abl was cotransfected along with receptor 1A, 1B or 
II in cos7 cells, and subjected to immunoprecipitation. It was observed that tyrosine 
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phosphorylation occurred in type 1 receptors and not type II when co-expressed with 
c-Abl (Fig. 6.1B). Moreover, since no tyrosine phosphorylation could be seen with 
co-expression of a kinase dead version of c-Abl (KD), this indicated a requirement for 
cAbl activation in this process (lane 6 in Fig 6.1B). To test whether this modification 
was physiological, c-Abl-/-Arg-/- double knockout (DKO) MEFs were used to 
immunoprecipitate endogenous BMPR1A. While similar levels of BMPR1A could be 
immunoprecipitated in both DKO and WT MEFs, DKO MEFs displayed lower levels 
of tyrosine phosphorylation compared to wild type (Fig. 6.1C). In addition, the 
compromised BMPR1A tyrosine phosphorylation in DKO MEFs was also seen in c-
Abl-/- MEFs, and this effect was further enhanced with BMP induction (Fig. 6.1D). It 
is possible that the homologue of c-Abl; Arg, might be needed to exert some 




6.2 Serial deletion analysis of BMPR1A reveals the carboxy terminal region is 
phosphorylated by c-Abl 
 
The intracellular portion of BMPR1A consists mainly of a ~32 kDa kinase domain, 
leaving a short tail of 13 aa at its carboxy terminus. In order to identify the region 
where c-Abl phosphorylates, deletion analysis was performed. 4 fragments with the 
lengths of 50 kDa, 45 kDa, 35 kDa or 30 kDa, with truncations starting from the 
carboxy terminus were PCR-cloned using the full length (FL) wild type BMPR1A as 
template, and HA-tagged. These deletions were labeled as deletion 1-4 (1 being the 
shortest fragment – 30 kDa), with each fragment consisting of a cluster of tyrosine 

























Fig. 6.1. Post-translational modification of BMP type I receptors by c-Abl.  
(A) Left - c-Abl mutant and wild type osteoblasts were harvested and subjected to 
RNA extraction and then RT-PCR. Little difference was observed in mRNA 
expression levels of BMPR 1A, 1B and II. Right – Protein levels of BMPR1A in c-
Abl MEFs. (B) Co-expression with c-Abl led to BMPR1A and BMPR1B tyrosine 
phosphorylation. HA-tagged BMPR1A and BMPRIB was expressed alone or co-
expressed with c-Abl in cos7 cells. BMP receptor was immunoprecipitated using anti-
HA antibodies and its tyrosine phosphorylation determined by western blot. Similarly, 
Flag-tagged BMPRII was immunoprecipitated with anti-Flag antibodies and observed 




























Fig. 6.1. Tyrosine phosphorylation of  BMP type I receptors by c-Abl (cont’d). 
(C) Reduced tyrosine phosphorylation of BMPR1A in c-Abl-/-Arg-/- MEFs. 
Endogenous BMPR1A was immunoprecipitated from cell lysates of mutant and 
control MEFs and tyrosine phosphorylation determined by western blot. (D) c-Abl-/- 
and wild type MEFs were grown to confluence, serum starved overnight and 15ng/ml 
BMP2 added the next day for 2.5 hours before harvesting cells. Cell lysates were 











expressed with c-Abl in cos7 cells and upon immunoprecitation of receptor via HA 
antibody, no tyrosine phosphorylation could be seen in all 4 deletion constructs except 
for the original FL receptor (results summarized in Fig. 6.2A right panel box). This 
leads to the finding that the tail-end region or carboxy terminus of BMPR1A is 
important in c-Abl regulation.  
 
 
6.3 BMPR1A Y453/467 residues are preferentially phosphorylated by Abl 
kinases 
 
In order to map the tyrosine residues in the tail-end region, an alignment of BMPR1A 
protein sequences of various animal species was made (Fig. 6.2B). 17 conserved 
tyrosine residues could be found in the entire cytoplasmic length of BMPR1A, with a 
cluster of 4 tyrosine residues being found at the extreme C-terminus, designated 
Y453, Y457, Y458 and Y467 (Fig. 6.2B). Mutagenesis of these four tyrosine residues 
were performed to generate four single tyrosine (Y) FL receptor mutants (labeled A to 
E) by replacing its original tyrosine residue to phenylalanine (F), so it does not affect 
protein confirmation, yet fail to be phophorylated by tyrosine kinases. Tyrosine 
phosphorylation by immunoprecipation was examined with these 4 single Y receptor 
mutants and no difference in the ability or strength for c-Abl phosphorylation was 
found (Fig. 6.3A). This led us to speculate that these Y residues might work in a 
group rather than singly to affect c-Abl action on BMPRs. Subsequently, 4 more 
tyrosine mutants were made with the first four mutants as templates, this time in 
various Y residue combinations as illustrated in Fig. 6.3B.  Phosphorylation analysis 
of these 4 combination mutants show that relative to FL wild type receptor, the 
tyrosine phosphorylation by c-Abl was abolished in the mutant I (Fig. 6.3B).  
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Moreover, the addition of BMP could enhance the c-Abl tyrosine phosphorylation of 
combination receptor mutants F, G, and H, but could not lift the severe inhibition in 
mutant I (Fig. 6.3C). The level of phosphorylation drops with receptor mutant H, thus 
suggesting that residues Y453 and Y467 are the tyrosine residues preferred by c-Abl. 
In addition, the degree of tyrosine phosphorylation by c-Abl is possibly quantity 
dependent, as receptor mutant F displayed highest phosphorylation, corresponding to 
higher c-Abl expression when compared to the rest. This overall effect was enhanced 
when the mutants were co-expressed with constitutive v-Abl (figure not shown), 
hence confirming that the integrity of Abl phosphorylation of BMPR1A depends 





















































Fig. 6.2. Mapping of BMPR1A phosphorylation site by c-Abl via receptor 
truncations. 
(A) The domain phosphorylated by c-Abl was mapped by serial deletions starting 
from C-terminus end. Four deletion mutants were created with their respective sizes 
stated on the left, compared to full length [FL] 1A receptor. Receptor deletion mutants 
#1 to 4 were co-expressed with c-Abl and tyrosine phosphorylation determined by 
western blot. The box in red summarizes the lack of tyrosine phosphorylation 
observed in all deletion mutants, when compared to typical FL tyrosine 
phosphorylation by c-Abl. (B) Diagram illustrating the alignment of C-terminal  
regions of BMPR1A of various species. Boxed in red are the conserved tyrosine 

















































Fig. 6.3. Identifying the BMPR1A C-terminal tyrosine residues phosphorylated 
by c-Abl via mutagenesis. 
(A) BMPR1A single tyrosine mutants do not affect the tyrosine phosphorylation 
status by c-Abl. Mutants A to E consist of a single (except D) mutation to replace 
tyrosine with phenylalanine (labeled F in blue). c-Abl was co-expressed with each of 
these mutants in cos7 and receptors immunoprecipitated using anti-HA antibodies. 
Tyrosine phosphorylation was determined by western blot. (B) More BMPR1A 
receptor mutants created from the templates of earlier single mutants. It was observed 
that while all 4 tyrosine residues could be phosphorylated, the major phosphorylation 
site for c-Abl remained at Y453/467 (mutant I consisting of all four mutated sites 








































Fig. 6.3.  BMP2 can enhance c-Abl mediated phosphorylation of BMPR1A on 
any of the all four tyrosine residues.  
(C) Receptor mutants F to I, together with wild type BMPR1A [FL], were co-
expressed with c-Abl in cos7 and serum starved overnight before adding 20ng/ml 
BMP2 for 30mins. Receptors were immunoprecipitated with anti-HA antibodies, and 
tyrosine phosphorylation determined by western blot. For control, lanes 1 and 2 were 





















6.4 BMPR1A Y453/457/458/467 mutant affects Smad1 activation, but not  
            Smad1 binding to receptor 
 
As BMPR1A is the bona fide activator of Smads1/5/8 and direct interaction is 
required, the effects of Smad1 activation was studied using a wild type Smad1 
construct and as a control; a mutant Smad1 that has the last 11aa deleted so it cannot 
be phosphorylated by BMPR1A (structural studies showed that the C-terminal final 
10 aa residues of Smad1 was shown to be flexible, while its carboxy tail end 
containing the final two serine residues of Ser-X-Ser, or SSXS motif was required for 
phosphorylation by BMPR1A (Qin et al., 2001, Shi and Massague, 2003). Co-
expression studies revealed that Smad1 activation was compromised in the mutant 
tyrosine receptor, while the binding of Smad1 to the wild type or tyrosine mutant 
receptor remains unaffected, with the mutant smad1 as well (Fig. 6.4). Hence, it is 
likely that c-Abl enhances Smad activation via these c-terminal tyrosine residues 
without interfering with Smad binding to the receptor.  
 
6.5 Mutant BMPR1A affects receptor complex formation 
 
 
In what ways can c-Abl influence the receptors and affect Smad activation? Since 
BMPRII is needed to phosphorylate BMPRIA at the unique GS box domain in order 
to further activate BMPR1A itself and thus Smads, the joining of both receptor types 
can affect downstream events. To understand the earliest cytoplasmic steps of BMP 
signaling, HA and Flag-tagged constructs containing BMPR1A and BMPRII 
respectively were co-expressed along with c-Abl. BMPR1A was then 















Fig. 6.4. Smad1 activation is compromised in the mutant BMPR1A.  
The mutant BMPR1A [m] carrying the 4 Y-F mutations and the wild type receptor 
were co-expressed with Smad1, or the mutant Smad1 (Smad1). Western blot 
analysis was used to determine Smad1 activation, using anti-phospho-Smad1/5/8 
antibody, and total Smad expression using anti-Smad1 antibody. For 
immunoprecipitation analysis, anti-HA antibodies were used for BMPR1A wild type 




















blot to look for the presence of BMPRII (Fig. 6.5). As seen in Fig 6.5, lanes 1-3 
revealed that BMPRII bound to BMPR1A, and this binding was markedly enhanced 
only with the addition of c-Abl, not its kinase dead form (KD). More importantly, 
lanes 6 and 7 show diminished binding of BMPRII, when the mutant BMPR1A was 
used. This signals that the 4 tyrosine sites regulated by c-Abl is needed for 
‘usual/normal’ receptor complex formation, as the lack of these sites can reduce 


























                               
 
 
Fig. 6.5. c-Abl facilitated the interaction between BMPRII and BMPR1A.  
The mutant BMPR1A [m] carrying the 4 Y-F mutations and BMPR1A wild type 
receptor were co-expressed with BMPRII (Flag-tagged) and c-Abl or c-Abl KD. 
BMPR1A was immunoprecipitated with anti-HA antibodies and the association to 






















6.6 Summary          
 
 
Since c-Abl could augment Smad activation, it is likely that c-Abl works upstream of 
Smads 1/5/8 and more work was needed to understand the first tier of BMP signaling 
that occurs upon BMP ligand binding. Immunoprecipitation studies showed that c-Abl 
could tyrosine phosphorylate BMP type I receptors and endogenous tyrosine 
phosphorylation of BMPR1A occurred in c-Abl primary cells. In the absence of c-
Abl, tyrosine phosphorylation was lower, and this was not due to differences in 
receptor transcript or protein expression levels (Fig 6.1). Hence, c-Abl acted on the 
BMP receptors and this phosphorylation action could be the main reason behind the 
enhanced Smad1/5/8 activation, since receptor Smads remain the only substrates of 
BMP receptor kinases.  
 
In order to map the region on BMPR1A that was phosphorylated by c-Abl, serial 
deletion analysis of the receptor was carried out on the cytoplasmic portion of the 
receptor, which mainly consisted of the S/T kinase domain. It was found that all 4 
truncations created could not be phosphorylated, hence the carboxy tail region of the 
receptor was targeted by c-Abl (Fig 6.2). Mapping of conserved tyrosine residues at 
this area was performed, by first aligning BMPR1A protein sequences of various 
mammalian species and further creating several single tyrosine mutations of the full 
length BMPR1A. Immunoprecipitation of these mutants showed little difference in 
phosphorylation status; hence more mutants were created in various combinations out 
of the four conserved tyrosines. Subsequently, c-Abl phosphorylation was severely 
abolished in mutant I containing all four tyrosines mutated to phenylalanine, with the 
preferred flanking tyrosine residues at Y453/Y467 favored by c-Abl (Fig 6.3). 
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The functionality of this receptor mutant I (Y453/457/458/467) on Smad activation 
was tested, and was shown that while it did not affect Smad1 binding to receptor, its 
co-expression with Smad1 decreased the Smad1 phosphorylation significantly, when 
compared to the strong Smad1 activation observed with wild type BMPR1A (Fig 6.4). 
More importantly, Fig 6.5 addressed the results observed in Fig 6.4, as the presence of 
c-Abl could enforce the binding of BMPRII to BMPR1A, while BMPRII binding to 
the mutant receptor was dramatically compromised, with or without c-Abl. This 
showed that the four tyrosine residues found on BMPR1A was essential for c-Abl to 
enhance receptor complex formation and thus promote receptor Smad activation, 
since the receptor type I and II complex was necessary for downstream Smad 






























CHAPTER 7  
 
 
A NEGATIVE ROLE OF C-ABL IN BMP-INDUCED ERK1/2 ACTIVATION 
 
 
With the earlier chapters demonstrating how c-Abl functions in the BMP pathway up-
regulate BMP target genes via Smads1/5/8, the key mediators of another equally 
important BMP-induced Smad-independent pathway is studied here, in the attempt to 
understand the purpose for MAPK-ERK activation seen in c-Abl-/- cells (chapter 4). 
 
The BMP-MAPK pathway is one of the pathways that were identified to be Smad-
independent. However, the downstream outcomes of activating mitogenic subfamilies 
ERK1/2, p38MAPK and JNK, vary extensively in cell type, kinetics and magnitude 
(Massague, 2000). Central to BMP-MAPK signaling is the activation of TAK1 (TGF-
 activated kinase), that is shown to function downstream of BMPs and TGF, as well 
as cytokines IL-1 and TNFα (Ninomiya-Tsuji et al., 1999). TAK1 was first identified 
as a MAP3K (Yamaguchi et al., 1995), and forms the crucial link between BMP 
receptors and MAPKs. TAK1, along with TAB1 (TAK1-binding protein-1), acts to 
mediate downstream MAPK pathways, by activating JNK and p38MAPK via 
MAP2Ks such as MKK3 and MKK6 (Delaney and Mlodzik, 2006, Moriguchi et al., 
1996). TAK1 works in tandem with TAB1 as it requires TAB1 for its initial activation 
and autophosphorylation at Thr184/187 in its kinase activation loop (Sakurai et al., 
2000).  
 
TAK1 is ubiquitously expressed during early development, and generally localized in 
the cytoplasm (Jadrich et al., 2003). TAK1 serves multiple roles in mouse 
development, as TAK1-/- mice are embryonic lethal (Shim et al., 2005). An important 
function of TAK1 signaling lies in the regulation of cell survival. TAK1-/- MEFs are 
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highly sensitive to TNFα-induced apoptosis and the loss of its kinase activity 
attenuates the TRAIL-induced activation of NFkB-p65 and MAPKs (Choo et al., 
2006, Thiefes et al., 2005). On the other hand, ectopic expression of TAK1 in induces 
cell death in Xenopus embryos (Shibuya et al., 1998). Here, the roles of TAK1 and 






7.1 Dual phases of ERK activation in c-Abl mutant osteoblasts is dependent 
on the duration of exposure to BMP2 
 
Early on, in chapter 4, it was observed that levels of activated ERK1/2 were elevated 
in c-Abl mutant osteoblasts and MEFs, when compared to its wild type counterpart. c-
Abl appears to have a repressive effect on MAPK/ERK activation, as in the absence 
of c-Abl, the level of activated ERK rises. In addition, reconstitution of viral c-Abl 
into knockout osteoblasts can rescue the lack of ERK inhibition in mutant cells (Fig 
4.1D). To examine the pattern of this activation, and also if ERK activation can be 
influenced by BMP signaling, BMP2 was added at various time points ranging from 0 
to 8hrs on wild type and c-Abl-/- osteoblasts (Fig 7.1A). It was observed that the 
normal wild type osteoblasts show transient ERK activation which peaks at 30mins 
from BMP stimulation, and plateau at the 2hr mark, this was then followed by a 
consecutive repression of phospho-ERK, to levels below the basal level. It is possible 
that the activation and repression waves under the influence of BMP could be 
involved in fine-tuning p16INK4a expression, as ERKs1/2 are transcriptional activators 
of p16INK4a (Lin et al., 1998). With c-Abl mutant osteoblasts, the ERK activation 
pattern differs, starting with higher basal p-ERK levels, followed by extended 
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transient ERK activation and the lack of ERK inhibition. These differences can be 
better observed by means of density measurement using absolute units (Fig 7.1B). 
Basal levels of activated MAPKK-MEK1/2, was also increased in c-Abl-/- osteoblasts, 
but remains constant with BMP2 induction. It is possible that c-Abl acts in an 
inhibitory manner on the upstream MAPKKKs, or there is a likelihood of crosstalk 
with the canonical RAS-RAF-MEK-ERK pathway. Nevertheless, either does not 
solely account for the ERK activation/repression pattern seen in mutant osteoblasts, 
and this underscores a novel role for c-Abl in BMP-induced ERK activity.  
 
Besides, blocking BMP2 activity for prolonged periods with antagonist noggin and 
chordin reversed the repression on ERK1/2 activation in wild type osteoblasts (Fig 
7.1C). This supports the earlier observation that the constant presence of BMPs plays 
a part in ERK regulation, and likely to be partially accountable for the enhanced ERK 




7.2 BMPR1A mutant mimics c-Abl-/- osteoblasts in ERK activation 
 
 
To further understand the relationship between c-Abl, and BMP-induced ERK 
activation, wild type and mutant-4Y BMPR1A was overexpressed with retrovirus in 
C2C12, a myoblastic cell line, as well as in primary osteoblasts to observe ERK 
activation. In both cases expression of mutant 4Y receptor led to an up-regulation of 
p-ERK1/2, compared to equivalent levels of expressed wild type 1A receptor (Fig 
7.2A and B). This is reminiscent of c-Abl knockout osteoblasts phenotype, suggesting 






Fig. 7.1. c-Abl regulates BMP2-induced ERK activation.  
(A) c-Abl deficiency altered BMP-induced ERK1/2 activation and/or suppression. 8 
individual osteoblast cultures of each cell type was pooled together and subjected to 
various time point treatments using 100ng/ml BMP2. Western blot was then used to 
determine activation of various kinases. (B) Quantitation data of phosphorylated ERK 
against total ERK values. (C) Blocking BMP signaling led to ERK activation. Using 
c-Abl primary osteoblasts, BMP antagonists noggin and chordin [N+C], or 100ng/ml 
BMP2 [B] was added to both wild type and mutant cells for 2-3 days and cells 
harvested for western blot analysis.  
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phosphorylation of BMPR1A might be important in controlling BMP-induced ERK 
activation.  
 
The TAB1-TAK1 complex has been implicated in BMP-mediated MAPK activation 
(Yamaguchi et al., 1999, von Bubnoff and Cho, 2001, Massague, 2000). It can be 
seen that the basal levels of activated TAK1, an upstream regulator of ERK 
(Hammaker et al., 2004), was enhanced in c-Abl mutant osteoblasts (Fig 7.1C), as 
well as MEFs (Fig 7.2C). On the other hand, the basal p-TAK1 levels in wild type 
osteoblasts and MEFs remain too low to be detected, indicating that c-Abl represses 
the TAB1-TAK1 complex signaling. Therefore, c-Abl functions upstream at the 
MAPKKK, as C2C12 cells overexpressing mutant 4Y receptor also leads to higher 
levels of activated TAK1 (Fig 7.2A). To find out if TAK1 was indeed required for 
BMP-induced ERK activation, TAK1 was knocked down in C2C12 cells. Using 
pooled TAK1 siRNAs and a transient transfection system based from Dharmacon, 
cells were kept in culture for >48hrs post transfection and 100ng/ml BMP2 added 
directly to culture media for various time points. Compared to the mock and siRNA 
non-target controls, the transient ERK1/2 activation was mitigated with the addition 
of BMP (Fig 7.2D). This implies that BMP-induced transient ERK1/2 activation 
utilizes TAK1, though it is unclear if c-Abl can engage TAK1 complex directly 
during the transient wave of ERK1/2 activation. 
 
 
7.3 Role of mutant BMPR1A in TAB1-TAK complex formation 
 
 
It was previously reported that the TAK1 and TAB1 molecules function downstream 





Fig. 7.2. c-Abl action on BMPR1A affects ERK activation.  
Mutant BMPR1A expression leads to enhanced ERK activation in C2C12 (A), as well 
as primary osteoblasts (B). Western blots show the innate levels of p-ERK1/2 and 
equivalent amounts of BMPR1A in cells overexpressing wild type 1A receptor or 
mutant receptor, compared to vector control infected cells. (C) Endogenous levels of 
activated TAK1 protein in c-Abl wild type and mutant MEFs. (D) Tak1 is required for 
transient BMP-induced ERK activation. TAK1 is silenced in C2C12 cells for 2 days 
and BMP2 added for short time points. Cells were harvested for western blot and 





embryos could revert the ventralization phenotype generated by constitutive 
BMPR1A activation that reproduced the effect of BMP2/4 (Shibuya et al., 1998). 
Essentially, it is important to look into the physical interaction of these molecules at 
the BMP receptor level as they are needed to tranduce the downstream effect of 
observed ERK activation seen in c-Abl-/- osteoblasts. Co-immunoprecipitation 
experiments in cos7 cells using mutant-4Y receptor showed that TAB1 displayed a 
higher affinity for the mutant BMPR1A compared to wild type receptor (Fig 7.3A). 
This experiment was repeated three times, with the average difference of 2.2 fold 
increase with density quantitation. This enhanced interaction could be direct, or 
mediated by endogenous proteins such as XIAP. Importantly, these results suggest 
that c-Abl deficiency can facilitate recruitment of TAB1-TAK1 complex to 
BMPR1A, and hence augment ERK1/2 activation. Fig 7.3B summarizes the results of 
all chapters, illustrating BMP activation of a Smad-dependent and Smad-independent 
pathway that converge to fine-tune the expression of p16INK4a which mediate c-Abl’s 

































Fig. 7.3. c-Abl phosphorylation of BMPR1A counters TAB1 interaction.  
(A) TAB1 was shown to display higher affinity for mutant 1A receptor [m] than wild 
type counterpart. Flag-tagged TAB1 and HA-tagged 1A receptors were co-expressed 
in cos7 cells. Receptors were immunoprecipitated using anti-HA antibodies and co-
purified TAB1 detected by western blot. (B) A diagram showing how c-Abl might be 















BMP signaling in osteoblasts gave rise to divergent outcomes of the MAPK-ERK1/2 
regulation. A short duration of BMP2 exposure (about 30mins) resulted in ERK 
activation, while long term BMP stimulation caused ERK repression. This suggests 
existence of a negative feedback regulation on BMP-induced ERKs, which was 
further confirmed by enhanced phospho-ERK levels when BMP signaling was 
impeded by adding BMP antagonists in the culture media (Fig 7.1C, lane 3). Yet, 
careful analysis of ERK activation by comparing c-Abl-/- with wild type cells revealed 
that the transient activation phase was not affected by c-Abl deficiency. Instead, 
differences could be observed with ERK repression at the longer time range of BMP2 
stimulation. c-Abl-/- osteoblasts originated with elevated basal phospho-ERK levels, 
comparable to the levels seen in noggin/chordin treated cells, yet repression of 
phospho-ERK was either delayed (Fig 7.1B), or lost (Fig 7.1C, lane 5), with long 
periods of BMP treatment. Moreover, cells expressing the mutant-4Y receptor also 
displayed higher phospho-ERK amounts in comparison to wild type BMPR1A (Fig 
7.2A and B), suggesting that tyrosine phosphorylation of BMPR1A by c-Abl serves 
some function in BMP-induced ERK repression.  
 
On the other hand, the mechanism by which BMPs regulate MAPK-ERK is not well 
understood. Previous studies suggest that BMPs might activate MAPKs through 
TAB1-TAK1 complex, joined by adaptor protein XIAP (Yamaguchi et al., 1999). 
XIAP was found to recruit this complex to BMPR1A, and this could subsequently 
result in MAP3K-TAK1 activation. Indeed, TAK1 plays a positive role in BMP-
induced ERK activation, as knockdown of Tak1 resulted in lower phospho-Erks at the 
basal level in response to BMP2 induction (Fig 7.2D). Moreover, TAB1 was found to 
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bind better to the mutant BMPR1A (Fig 7.3A), and since TAB1 is needed to activate 
TAK1, this correlates well with the subsequent observed elevated downstream 
activation of MAP3K-TAK1, MAPKK-MEKK1 and finally, MAPK-ERKs, in c-Abl 








































BMP SIGNALING IN BCR-ABL AND THE SUSTAINANCE OF BONE 
MARROW PROJENITOR CELL POPULATION 
 
Studies described in the previous chapters support the notion that the cytoplasmic 
form of c-Abl acts on BMP type 1 receptors to affect downstream signaling to 
enhance Id1 expression, to down-regulate Erk1/2 activation, leading to repression of 
p16INK4a expression. As a result, the net outcome favors osteoblast proliferation. 
Another perspective into Abl signaling would be to understand the etiology of BCR-
ABL oncogenesis in the development of CML. 
 
BCR-ABL expression is required for the maintenance of CML. What are the signaling 
pathways involved? BCR-ABL targets many common signaling pathways to block 
apoptosis, promote proliferation and affect cell adhesion characteristics, processes 
that are advantageous for cellular transformation. The PI3K-AKT pathway is 
activated by BCR-ABL, likely to target AKT-mediated inactivation of FoxO 
transcription factors that affect apoptosis through p27Kip1 (Gesbert et al., 2000) and 
Bim (Kuribara et al., 2004). Proliferation is promoted by activation of the mitogenic 
Ras-Raf-MEK-ERK pathway, by recruitment of adaptors Grb2-Gab2 (Million and 
Van Etten, 2000). Yet, specific roles for BCR-ABL activation of p38-MAPK and 
repression of ERK was reported (Kohmura et al., 2004). The JAK/STAT pathway is 
involved in BCR-ABL transformation as STAT5a could abrogate hematopoietic cell 
dependence on cytokines (reviewed in Steelman et al., 2004). BCR-ABL can also 
alter actin cytoskeleton dynamics by binding to cytoskeletal proteins such as Sos-1 
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(Sini et al., 2004), and activating related pathways to enhance cell adhesion to the 
extra-cellular matrix (Feller, 2001).  
 
From the current understanding of BCR-ABL in signaling pathways, this chapter 






8.1 BCR-Abl potentiates BMP-induced Id1 expression, and can be inhibited 
by imatinib/STI571 treatment 
 
Using BCR-ABL positive CML human cell line K562, the endogenous protein levels 
of Id1 and phosphorylated smads1/5/8 were found to be highly expressed, when 
compared to its negative counterpart (myeloblastic cell line HL-60) (Fig. 8.1A). This 
suggests that increased Smad-Id1 signaling correlate with higher levels of Abl kinase 
activity.  
 
A preliminary look at downstream effects of suppressing BCR-ABL activity by 
adding inhibitor imatinib into culture media for 1 and 3 days demonstrated that basal 
Id1 expression is completely abolished even in K562 cells in 1 day, or 3 day cultures 
(Fig. 8.1B).  
 
In addition, the presence of BMP2 in culture could further induce Id1 expression after 
6 hrs of treatment (Fig. 8.1C, lanes 5 and 6), with the response more pronounced at 
the transcript levels when compared to HL60 cells (Fig. 8.1D). Interestingly, 
pretreatment of cells with imatinib prior to BMP2 treatment led to a huge reduction of 
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Id1 induction under BMP stimulation (Fig. 8.1C-D, lanes 4 and 8). This shows that 
BCR-ABL positive cells respond to BMPs, and it is due to this active BMP signaling 
that Id1 is enhanced. It appears that Id1 serves as an important target of BCR-ABL 
kinase activity, which is effectively repressed upon imatinib treatment.  
 
Likewise, limiting the canonical BMP2/4 circulation in culture media using BMP 
antagonists noggin and chordin at recommended ED50 dosage showed that the high 
levels of basal Id1 in K562 cells could be reduced by about more than half after 72 hrs 
(Fig. 8.1E) This implies that a positive feedback mechanism of BMP signaling 
pathway exists in myeloid cell types , and is in part needed to maintain constant, high 
levels of Id1 expression, along with other pathways. The similar fashion in which 
HL60 cells behave in response to noggin and chordin confirms that Abl in essence, 
rely on Id1 as a positive downstream mediator in encouraging survival or growth, 
albeit with the “amplified” Id1 level in BCR-ABL cells, it may possibly promote 
aggressive growth signals.  
 
8.2 p16INK4a expression and the ageing of the bone marrow cells  
 
 
In vivo, osteoblasts reside in the bone marrow, and to gain insight into the influence of 
its microenvironment, bone marrow cells were pooled from adult mice of three age 
groups; at 4, 12 and 17 months to look at the effects of age on HSCs that consist of 
virtually all progenitor precursor cell populations of myeloid lymphoid and erythroid 
lineage.  p16INK4a expression at the protein level in these bone marrow cells increased 
with age (Fig. 8.2A), while this can be more clearly seen at the mRNA expression 










Fig. 8.1. Profile of Id1 gene regulation in an innate activated Abl cell line model.  
(A) Constitutive BCR-ABL activity in K562 cells showed that endogenous Id1 
protein expression was elevated, along with activated BMP-Smads 1/5/8 when 
compared to BCR-ABL negative HL60 cells. (B) HL60 and K562 suspension cells 
were counted and seeded in T25cm2 flasks, at a cell density that encouraged 
proliferation (with exception of day 3 - K562 cells seeded at a lower density to 
parallel growth rate for HL60 cells as K562 cells proliferate faster). Cells were then 
harvested for western the following day (day 0), followed by days 1 and 3. In lanes 7 














Fig. 8.1. BCR-ABL can potentiate Id1 expression via the BMP pathway.  
(C) Western blot shows that imatinib mesylate can overcome BMP-induced Id1 in 
K562 cells.  Cells were pretreated with 1uM imatinib for 4 hrs, before adding 
100ng/ml BMP2 for 6hrs. (D) RT-PCR shows mRNA profile of Id1 under the same 
conditions used in Fig 8.1C. (E) Blocking BMP signaling by adding noggin and 













been reported in normal human and mice tissues, and may reflect a role for p16INK4a  
in cellular senescence in vivo (Nielsen et al., 1999). Normal p16INK4a -mediated aging 
may take place in the bone marrow, with increasing intensity at an older age, as 
senescence of bone marrow stroma may decrease the ability of marrow cells to form 













































Fig. 8.2. p16INK4a expression in the bone marrow of aging mice.  
(A) Bone marrow cells were extracted from long bones (femur and tibia) of mice. 3 
mice of each age group; 4mths, 12 mths and 17mths were pooled. Cells were rid of 
red blood cells, and lysed with protein lysis buffer for western blot analysis to probe 
for p16INK4a and Id1 expression. (B) Bone marrow cells were obtained from the above 
mentioned and cell pellet subjected to RNA extraction, RT-PCR, to measure p16INK4a 



















8.3 Summary  
 
 
From the above results, it can be concluded that a BMP-Id1 pathway also exists in 
BCR-ABL positive cells, and mirrors the positive role that c-Abl plays in bone 
development. Id1, responsible for promoting proliferation signals and inhibiting 
initiation of differentiation programs, is heavily amplified in BCR-ABL positive cells. 
With K562 cells, the pattern of increased Id1 induction reflects the intensity, or the 
degree of innate Abl kinase activity, which was effectively suppressed upon imatinib 
treatment (Fig 8.1A and B). This suggests that the sustained, yet stable expression of 
high levels of Id1 is highly dependent on BCR-ABL kinase activity, along with other 
tyrosine kinases that imatinib/STI571 inhibits.  
 
This phenomenon was enhanced with the addition of BMP2, with Id1 up- regulated at 
the mRNA level. Imatinib also severely repressed BMP-induced Id1 (Fig 8.1C and 
D). The BMP-Smad pathway forms an integral part of the many pathways BCR-ABL 
targets (Steelman et al., 2004), since the lack/inhibition of BMP signaling feedback 
(Fig8.1E) and adding imatinib to osteoblasts give a similar reactions; both represses 
Id1 expression, along with down-regulation of activated Smads (results not shown), in 
contrary to the presence of an intact, overactive BMP system in K562 cells.  
 
Also, a salient feature of chronic phase CML is the subtle but consistent increase in 
immature and mature myeloid cells, which later develops into abnormally high levels 
of immature myeloblasts (blasts crisis phase) (Wong and Witte, 2004). Blasts cells 
originate from the bone marrow. Cellular barriers to such aggressive tumorigenesis 
must be in place, and p16INK4a –mediated stem cell senescence might be one such 
barrier. The analysis of bone marrow stomal cells in wild type mice of various ages 
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also demonstrates the concomitant increase of p16INK4a (Fig 8.2). While Id1 
expression diminish in 17-18mth old mice, surmises the fact that regulation of 
p16INK4a expression may be largely controlled by Id1, and the role of BMPs in the 
marrow microenvironment cannot be discounted.  
   
BCR-ABL induced Id1 via BMP-Smads in CML is complicated by the multitude of 
other intracellular signaling pathways taking place. Nevertheless, the main reasons 
could be to target and block p16INK4a -mediated senescence, while promoting aberrant 
clonal cell expansion. Indeed, it was reported that BMPs play a role in mouse ES cells 
was to encourage self-renewal, rather than block ES cell differentiation in neural crest 
formation (Varga and Wrana, 2005). Yet, it is also possible that BMPs have more 
discrete roles on ES cells in post-natal physiology (or adult tissue regeneration), and 
the emphasis might shift to regulate cell expansion and survival. 
 
Hence, these results provide an insight into how CML disease state is maintained in 










CHAPTER 9   
 
 
DISCUSSION AND FUTURE PERSPECTIVES 
 
 
A link for osteoblast premature senescence and aging associated osteoporosis 
 
 
c-Abl knockout mice display aging associated osteoporosis, characterized by defects 
in osteoblast function and numbers, but not osteoclasts (Li et al., 2000). Ex vivo 
analysis of c-Abl-/- osteoblast cultures painted a profile that matched this phenotype, 
as isolated mutant osteoblasts have reduced proliferation capacity, along with 
accelerated senescence as demonstrated by increased -galactosidase staining and 
p16INK4a expression. This premature senescence could be mediated by increased 
p16INK4a expression, resulted from increased ERK1/2 activation and decreased Id1 
expression (Chapter 4). In adults, constant bone remodeling is essential for bone 
homeostasis and repair, which accounts for an estimated replacement of 25% of 
trabecular bone and 3% of cortical bone annually (Manolagas and Jilka, 1995). A 
reduction in the growth potential of osteoprogenitors can lead to undesirable 
consequences, such as an insufficient supply of mature osteoblasts, or the induction of 
senescence which might also interfere with the function of neighboring cells (Chan 
and Duque, 2002). In addition, in vivo studies on the long bones of c-Abl-/- adult mice 
revealed higher levels of p16INK4a staining in marrow region near the hyperchondrial 
growth plate, and higher levels of p16INK4a mRNA, while lesser number of osteoblasts 
per bone surface was reported. This provides a rationale for c-Abl-/- mice as a suitable 
mouse model to associate premature osteoblast senescence with senile osteoporosis. 
The concept that cellular senescence contributes to tissue aging, such as osteopenia of 
bones, parallels the study of PASG, a proliferation associated SNF2-like gene in 
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which its deficiency led to premature aging phenotypes, including osteoporosis (Sun 
et al., 2004). 
 
Another feature associated with aging is cell susceptibility to stress. Cells of patients 
with progeroid syndromes were more prone to hypersensitivity to stress-induced cell 
death. c-Abl have been implicated in cellular response to oxidative stress, and it was 
found that c-Abl-/- osteoblasts and c-Abl-/- Argl-/- MEFs showed higher susceptibility to 
oxidative damage (Li et al., 2004, Cao et al., 2003). Oxidative stress have also been 
known to induce senescence in many cell types, and it is important to determine if the 
up-regulation of p16INK4a, and decrease in Id1 seen in senescent c-Abl-/- osteoblasts 
were the consequence of a response to oxidative stress, apart from premature 
senescence. Experiments using hydrogen peroxide to induce oxidative damage on c-
Abl osteoblasts, and conversely the use of ROS (reactive oxygen species) blocker; 
NAC (N’ acetylcysteine), did not alter the expression of p16INK4a and Id1 
significantly, although senescence was induced in the former (results not shown).  
This confirmed that changes in p16INK4a or Id1 expression remains unaffected by 
oxidative stress-induced senescence, hence the hypersensitivity to oxidative stress and 
premature senescence in c-Abl-/-  osteoblasts are independently modulated by c-Abl. 
 
This study highlights the importance of p16INK4a in the aging process of osteblasts. 
Premature senescence of c-Abl-/- osteoblasts were found to be the result of p16INK4a up 
regulation, consistent with the studies by other groups that report the accumulation of  
p16INK4a in aged cells and the reduction of Id1, or cells deficient for p16INK4a are 
resistant to senescence (Huot et al., 2002, Alani et al., 2001). Moreover, the interest in 
p16INK4a mediated aging was renewed when up regulation of p16INK4a was shown to 
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induce an aging-dependent decrease of forebrain progenitors and pancreatic beta-cells 
(Molofsky et al., 2006, Krishnamurthy et al., 2006).  
 
Nonetheless, c-Abl-/- mice displayed other phenotypes reminiscent of an aging 
organism such as premature death, thymus atrophy and lymphopenia, other than 
osteoporosis. Taken together, the mouse phenotypes, the hypersensitivity to oxidative 
stress, and the premature senescence of osteoblasts suggest that c-Abl plays a role in 
bone remodeling and general organismal aging. The role of p16INK4a up-regulation 
and BMP activated pathways may also contribute to c-Abl function in other aspects of 
development and homeostasis.  
 
 
A role for c-Abl in BMP signaling, ERK1/2 activation and Id1 induction 
 
 
In chapters 4 and 5, ERKs, and Id1 were identified as major players involved in 
p16INK4a mediated aging of c-Abl-/- osteoblasts. Without c-Abl, excessive MAPK-ERK   
activation and Id1 repression was observed. This was in line with established studies 
that stated ERKs to be positive regulators, while Id1 a negative regulator of p16INK4a, 
and Id1 along with p16INK4a, influenced the senescence of human and murine cells 
(Lowe and Sherr, 2003).  
 
BMPs are secreted by osteoblasts and are required for bone formation and 
regeneration (Chen et al., 2004, Tsuji et al., 2006). It was observed that blocking 
BMPs with antagonists noggin and chordin could up regulate p16INK4a, while long 
term BMP2 treatment down-regulated p16INK4a levels. These findings suggest that 
BMPs modulate p16INK4a expression via the ERK1/2 and Smad1/5/8-Id1 pathways. 
Yet, p16INK4a regulation may be more complicated due to inputs of ERK1/2 from 
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growth factors, as well as the feedback regulators of BMP-Smad signaling such as 
inhibitory Smads. However, the Id1 and ERK signaling pathways that govern p16INK4a 
expression were found to act independent of each other as Id1 remains unaffected by 
MEK1/2 inhibition with U012S (MEK1/2 activates ERK1/2 -Fig 4.1B). The fact that 
c-Abl affects ERK activation and Id1 hints at the possibility of a BMP-Smad and 
BMP-Smad-independent pathway taking place, as c-Abl have been shown to 
participate in TGF activated, Smad-independent pathway (Daniels et al., 2004, 
Wang et al., 2005). Thus it remains likely that the BMP pathway operates in 
cooperation with other signaling pathways to control p16INK4a transcription, as in the 
case of stem cell regulation (Zhang and Li, 2005).  
 
Furthermore, these findings suggest that BMPs play a role in osteoprogenitor 
expansion. We found that Id1, when overexpressed could extend the lifespan of c-Abl-
/-
 osteoblasts, indicating the down-regulation of Id1 by c-Abl deficiency contributed to 
the reduced proliferation capacity of c-Abl-/- osteoblasts, via p16INK4a. Since BMP 
inhibition by noggin and chordin not only impedes osteoblast differentiation, but also 
cause the reduction of Id1 and elevation of p16INK4a in wild type cells, implies that 
autocrine BMPs may function to promote osteoblast proliferation via Id1. This idea is 
in agreement with the finding that targeted noggin overexpression in osteoblasts led to 
the depletion of osteoprogenitor cells of 8 month old mice (Wu et al., 2003). The 
question remains on how BMPs work in unison with other pathways to regulate 
osteoblast expansion and osteoblast differentiation. 
 




c-Abl was able to up-regulate Smad activation by modifying BMP type I receptors, 
whereby the tyrosine residues found at the C-terminus was necessary for robust 
complex formation of type I and type II receptors.  It was speculated that type IV c-
Abl, which harbors a myristoylation signal and is potentially attached to the plasma 
membrane, was responsible for this phosphorylation. On the other hand, the 
expression pattern of BMPR1B was limited to various embryonic tissues; while 
BMPR1A could be ubiquitously expressed in developing embryos (Kawabata et al., 
1998) provided a rationale to study BMPR1A regulation by c-Abl. Nevertheless, a 
similar mode of action on BMPR1B by c-Abl would be probable since both BMP type 
1 receptors, BMPR1A and BMPR1B; possesses 85% aa sequence identity similarity 
to each other and they share almost the same conserved tyrosine residues. The 
functions of both type I receptors appear to confer unique roles in bone development 
(Kawakami et al., 1996, in vitro studies by Chen et al., 1998 and Kaps et al., 2004), 
yet overlapping functions were also reported (Yoon et al., 2005). Nevertheless, it 
appears that BMPR1A is ultimately needed for induction of mesoderm formation 
/embryogenesis since bmpr1a-/- mice are embryonic lethal (Mishina et al., 1995), 
compared to the less severe phenotype of null mutation in BMPR1B gene. 
Comparatively, the phenotypes of c-Abl-/- mice could provide clues to understand the 
functions of BMP receptors in neo-natal and post-natal development, such as and the 
maintenance of tissue homeostasis and repair, this importance is stressed in mouse 
postnatal bone formation by Zhao et al., 2002. 
 
It also appears that BMPRII, harboring a large cytoplasmic tail of about 600 aa 
following the kinase domain, does not play a role in c-Abl regulation of the BMP 
signaling, but is required for BMPR1A activation. Indeed it was previously reported 
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that this tail domain held little significance for BMP-Smad mediated signaling, though 
it may play a role in mediating other pathways (Wieser et al., 1993, Nishihara et al., 
2002). In our study, a novel role for the C-terminal domain of BMPR1A is uncovered, 
other than its function in Smad activation.  
 
The findings that c-Abl regulates BMPR1A adds to the list of cited examples of BMP 
receptor post-translational modification by kinases. BMPRII was found to be 
regulated by interaction with LIM kinase (Foletta et al., 2003), c-kit, a stem cell factor 
receptor (Hassel et al., 2006) c-Src; a c-Abl related kinase (Wong et al., 2005), and 
TrkC (Jin et al.,2007) while GD5-mediated BMPR1B signaling was affected by 
receptor tyrosine kinase Ror2 (Sammar et al., 2004). However, the functional 
significance of some of these kinase-receptor interactions has yet to be validated in in 
vivo settings. Apart from phosphorylation, other modes of modification have also 
been reported. Sulfation was found to be required for BMP2 induction of Id1 (Osses 
et al., 2006), while pamitylolation was found to occur on BMP receptors (by personal 
correspondence with Dr. Leong Wai Fook), and epigenetic silencing of BMPR1B 
determines cell-fate decision of glioma stem cells (Lee et al., 2008). The ever 
increasing discovery of various post-translational events on BMP receptors shows the 
complex regulation of an apparently simple three-tier signaling pathway. 
 
Also, steps taken to study the structural and/or physical aspects of receptor regulation 
provide better understanding of receptor dynamics in the cell membrane. Pre-
complexed BMPR1A and BMPRII at the plasma membrane (or PRCs- Pre-formed 
receptor complexes) forms a precedence for canonical receptor-Smad activation, 
while in the case of latent complex formation induced upon BMP ligand binding (or 
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BISCs- BMP-induced signaling complexes) leads to non-Smad MAPK signaling 
(Nohe et al., 2002) Hence, this supports the data that c-Abl facilitation of pre-
complexed IA and II, enhances Smad activation and thus transcription of downstream 
target genes such as Id1. In addition, BMP receptors exist in a dynamic state as they 
not only form clusters or enact rearrangement upon BMP induction, but also interact 
with caveolae compartments (Nohe et al., 2003 and 2004), and exhibit different 
modes of BMP receptor endocytosis that pre-determines preference for Smad-
dependent or Smad-independent signaling (Hartung et al., 2006). c-Abl might also 
regulate the BMP receptors via other mechanisms such as the ones mentioned above, 
or to affect receptor degradation, and is worth exploring further in the future. 
 
The consequent activation of BMP receptors at the cell membrane upon BMP ligand 
binding not only triggers the receptor Smad activation cascade, but also the lesser 
known Tak1-MAPK pathway. In chapter 7, the role and importance of TAK1 in 
BMP-MAPK signaling is explored. ERK1/2 was found to be repressed with long 
durations of BMP treatment, while a transient activation is initially observed within 
30 mins of BMP addition. What is the role of ERK activation and repression in the 
time frame of BMP signaling? We argue that the function for ERK activation and 
repression by c-Abl might serve disparate purposes, and although ERK activation 
involves Tak1 and its activation is heightened in c-Abl-/- osteblasts, this could reflect 
the consititutve general repressive action of c-Abl on ERKs. However, c-Abl 
activation of ERKs, albeit a short one, may be important in regulating or work in 
synergy with other growth related MAPK pathways to promote proliferation. To a 
lesser extent, another possibility would be to hinder BMP-Smad signaling as ERKs 
can phosphorylate the linker region of receptor Smads and prevent its translocation 
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(Massague, 2003). Hence, the transient activation of ERK under BMP, might also 
contribute to the phenotype seen in c-Abl-/- mice through activation of other pathways. 
 
 
On the other hand, what do the repression of ERK1/2 in BMP signaling serves in the 
context of bone development? An example of BMP signaling required for ERK 
repression was to counter key effectors (ERK being one of them) of the FGF pathway 
in the growth plate region of bone (Yoon et al., 2006). ERK repression was also found 
to be required for BMP induction of early osteoblast genes in human marrow cells 
(Osyczka and Leboy, 2005). Long term BMP-induced inhibition of MAPK/ERK may 
also have an influence on cell survival, as TGF family members have been reported 
to enlist MAPKs in activation of apoptotic pathways (Massague, 2000). The XIAP 
adapter protein, constitutively bound to BMPR1A and interacts with Tab1 
(Yamaguchi et al., 1999), is likely to be involved, and could also be the link for 
increased apoptotic osteoblasts seen in the TUNEL immunostaining of c-Abl-/- long 
bones (Fig 3.3), as it has been reported that BMP signaling is necessary for induction 
of apoptosis of neural progenitors, by the combined actions of Smad and TAK1 
(Kendall et al., 2005). It will be interesting to further study the role of XIAP, as well 
as if the apoptotic signaling cascade is triggered, as BMP-MAPK signaling is favored 
due to defective BMP-Smad pathway in c-Abl-/- mice. 
 
In our study, c-Abl acts to stabilize BMP receptor complex formation, which 
augments Smad activation. Concurrently, this c-Abl-BMPR1-BMPRII complex acts 
to repress the action of TAK1-TAB1 activation by physical interference. The 
subsequent increase in Id1 and down-regulation of active ERKs works hand in hand 
to fine-tune p16INK4a gene expression, so it can be inferred that BMP-TAK1 activation 
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serves to oppose canonical BMP-Smad pathway in c-Abl-/- osteoblasts, summed up 
earlier in Fig 7.3B. Nevertheless, more work will also be needed to understand the 
mechanism of BMP-MAPK signaling and its influence on BMP-Smad signaling, 
emphasized in Qi et al., 2004, and Zhang and Li, 2005. This is because the negative 
impact of TAK1 activation on BMP-Smad activation could be far greater than 
anticipated as activated TAK1 has been shown to bind to all Smads and Tak1 
overexpression attenuated the BMP-dependent differentiation potential, as well as 
block the transcription of osteogenic marker genes in C3H10T½ cells (Hoffman et al., 
2005). Therefore, the subtle actions of c-Abl on BMP receptors exemplify the 
multitude stages of BMP regulation that affects the transcriptional outcome and thus 
the cell’s response to BMPs. 
 
BMPs and Abl kinases; involvement in oncogene-induced senescence  
 
 
In retrospect, the previous findings raised some important questions on Abl function. 
The phenomenon of replicative senescence is postulated to act as an important barrier 
against neoplasticity and tumor formation (Sherr and DePinho, 2000, Mathon and 
Lloyd, 2001), and can be seen in normal cells harboring enforced expression of 
cancer-promoting genes such as Ras; termed oncogene-induced senescence, which 
requires both intact p53 and p16INK4a-Rb pathways (Braig et al., 2005, Benanti and 
Galloway, 2004). While it was shown that the loss of c-Abl induces high p16INK4a 
expression and leads to premature osteoblast senescence, BCR-ABL on the other 
hand, was also able to activate BMP-Smad-Id1 pathway and it is likely that BCR-
ABL prevention of regular stem cell senescence acts as a viable mechanism to support 
HSC transformation.  
 
 142
There is other evidence to support this notion. Firstly, the persistent and sustained 
high levels of Id1 expression seen in BCR-ABL positive cells was likely to act as an 
indispensable target that drives indefinite self-renewal capacity and expansion of 
myeloid progenitors, possibly at different time frames of cell fate decision. Though 
the role of Id proteins demonstrated some functional redundancy in the immune 
system, specificity of each Id protein function was essential. It was found that Id1, 
and not Id3, maintains long-term repopulating HSC cell expansion (Perry et al., 
2007), while Id2 expression peaked in cells undergoing terminal myeloid 
differentiation (Ishiguro et al., 1996). Also, the ectopic expression of BCR-ABL 
could sustain the self-renewal of mouse ES cells (Nakamura et al., 2005).  
 
It appears that Id1 up regulation by BCR-ABL serves as a signaling midpoint in the 
cross-talk and activation of many pathways. Id1 was singled out in several examples 
in the study of BCR-ABL malignancy such as; to promote invasiveness of leukemic 
cells via matrix metalloproteinase 9 (MMP9) (Nieborowska-Skorska et al., 2006), via 
Akt inactivation of FOXO3a in K562 cells (Birkenkamp et al., 2007) and C/EBPα 
mediated myeloid differentiation (Wagner et al., 2006). Id1 also participate in 
promoting angiogenesis (Sikder et al., 2003, Ruzinova et al., 2003), while c-Abl-/- 
mice showed defects in angiogenesis (Nunes et al., 2001) which could in part be due 
to compromised Id1 levels.  
 
Secondly, another essential function of Id1 is to regulate cell cycle events, via 
suppression of p16INK4a, along with other cyclin-dependent kinases and/or inhibitors. 
Despite the multitude of proteins that keep p16INK4a  expression tightly controlled, Fig 
8.2 demonstrated that p16INK4a expression stably increases with age, while Id1 
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expression is lost, in the bone marrow of aged heterologous mice. Therefore, it 
appears that a ‘theshold’ level of Id1 expression is required in the bone marrow to 
oppose p16INK4a–mediated senescence, though it will be of interest to find out if the 
individual cell types found in the bone marrow exhibit similar profiles with age. 
Nevertheless, Morrison and team studied the in vivo properties of murine marrow 
cells and found that old mice had functionally incapable HSCs compared to young 
mice, despite being proliferative (Morrison et al., 1996). It is not fully understood if 
replicative senescence can only be triggered following cessation of cell expansion or 
that they can both occur concurrently, but Id1 plays important roles in these two 
outcomes of cell fate, and its time and amount of expression may be the determinant. 
This also raised the question of whether intrinsic determinants or the aging 
microenvironment could give rise to leukemia in aging subjects. Since p16INK4a has 
been implicated on the phenomena of stem cell aging (Janzen et al., 2006), it is 
imperative to embrace the role BMPs and senescent osteoblasts play in the bone 
marrow microenvironment as well. BMP signaling have been indirectly implicated in 
study that cited the lack of JunB gave rise to a CML like disorder in mice, stemming 
from HSCs (Passegue et al., 2004), since JunB is a BMP target gene. c-Myc, another 
transcription factor that also can be induced by BMP2, triggers p16INK4a mediated 
senescence in tumor cells when inactivated (Wu et al., 2007). More importantly, the 
role of osteoblasts is to provide a stem cell niche for HSC expansion in the marrow, 
and failure to maintain this niche may underlie the pathogenesis of senile osteoporosis 
(Calvi et al., 2003, Zhang et al., 2003, Visnjic et al., 2004 and reviewed by Calvi, 
2006). Our findings suggest that BCR-ABL enhanced expression of Id1 and 
repression of p16INK4a might be mediated by the BMPs circulating in the bone 
marrow, while BMPs are secreted by osteoblasts. Hence the secondary effect of aging 
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osteoblasts and disrupted BMP signaling might overall contribute to other immune 
cell defects as well as development of leukemias.  
 
Moreover, it was found that the expression of p16INK4a was silenced in K562 cells 
(data not shown), as well as in leukemic cells of many CML patients, indicating the 
importance of down-regulating p16INK4a in CML development. This was exemplified 
with an example of p16INK4a repression by Bmi-1 that led to premature senescence of 
stem cells (Itahana et al., 2003).Hence, expressing high levels of Id1 contributes to 
delaying and/or inhibiting the onset of senescence program of myeloid cells by 
keeping p16INK4a permanently repressed, thus facilitating transformation and 
development of leukemia. This might have implications in the rapid, yet debilitating 
progression of chronic phase to blast crisis stage of CML, where imatinib prognosis is 
poor (Wong and Witte, 2004), while the mechanisms that control the rate of disease 
progression remains unclear.  
 
Moreover, a study has shown that imatinib treatment of CML was found to disturb 
bone remodeling, as patients show reduced bone formation (Berman et al.,2006). 
Thus, the possible toxicity of long-term imatinib mesylate therapy in humans have to 
be questioned, since it also inhibits the activity of c-Abl, whose deficient mice leads 
to senile osteoporosis, along with other defects. Therefore, long-term inhibition of abl 
kinase activity might lead to shortage of osteoblasts and osteopenia through the 
regulation of BMP activated Smad1/5/8 and MAPK pathways. Compounded by the 
ever increasing imatinib resistance in patients, and efforts to repress BCR-ABL 
transcripts or protein levels have led to limited progress due to the kinase-dependent 
nature CML pathogenesis (reviewed in O’Hare et al., 2007), perhaps targeting these 
key mediators may provide some relief to a long standing problem?  
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    Tris solution  [pH7.4]   20mM 
    NaCl     100mM 
    NP-40     0.5% 
    EDTA     0.5mM 
    PMSF     0.5mM 






TBST Buffer (30X stock) 
 
 
    Sodium Chloride   480g 




Top up to 2L using ddH20 and adjust pH to 7.6 with 5M HCl. Dilute stock solution to 
1X and add Tween 20 at 1/1000 (1ml per 1L solution), stir thoroughly before use. 









APPENDIX B: CELL CULTURE REAGENT          
 
 
PlatE culture medium 
 
DMEM    - 
FBS     10% 
Pen/Strep    1X 
Blasticidin    10ug/ml 
Puromycin    1ug/ml 
 













X-Gal     0.1% (w/v) 
Citric acid/ sodium phosphate  
(pH6.0)    40mM  
Potassium ferrocyanide  5mM 
Potassium ferricyanide  5mM   
NaCl     150mM 















Stacking gel (4%) 
    30% acrylamide (29:1)  1.3ml 
    ddH2O     6.1ml 
    0.5M Tris-HCL pH 6.8  2.5ml 
    10% SDS    100ul 
    10% APS (w/v)   100ul 
    TEMED       10ul 




Resolving gel (15%) 
30% acrylamide (29:1)  5.0ml 
    ddH2O     2.36ml 
    1.5M Tris-HCL pH 8.8  2.5ml 
    10% SDS    100ul 
    10% APS (w/v)   100ul 
    TEMED       10ul 





















Imatinib (STI571) (Novartis) 
Dilute amphophilic pellet to 1mM stock concentration with sterile ddH2O. Dissolve 
thoroughly and store in aliquots at -20oC. Stock can be directly used and diluted with 
media to achieve final concentration of 1uM (1000x dilution). 
 
rhBMP2 (R&D systems and iDNA)  
1mg lyphophilic pellet is diluted to 10ug/ml working stock with 1ml of dilution buffer 
(0.1% BSA in PBS). Dissolve thoroughly and store in aliquots at -20oC.  The same 
dilution buffer is used to further dilute BMP if necessary. 
 
Mouse recombinant Noggin (R&D systems)  
25ug lyophilized pellet dissolved with 500ul filtered PBS (with 0.1% BSA as carrier) 
to create a 50ug/ml working stock.  
 
Mouse recombinant Chordin (R&D systems) 
50ug lyophilized pellet dissolved with 500ul filtered PBS (with 0.1% BSA as carrier) 
to create a 100ug/ml working stock. 
 
MEK inhibitor U0126 (Promega) 
1mg pellet was resuspended with 234ul DMSO to prepare a 10mM working stock. 
Solution remains stable for 1 week at -20oC.  
 
Puromycin dihydrochloride (USBiological) 
100mg of puromycin powder was weighed out and dissolved with 4mls of ddH20 to 
prepare a working stock of 25mg/ml. Solution was filter-sterilized before storing in 
aliquots at -20oC. 
   
 
 
 
 
 
